WO2014075157A1 - Composition and formulation based on coffee oil, and uses thereof - Google Patents

Composition and formulation based on coffee oil, and uses thereof Download PDF

Info

Publication number
WO2014075157A1
WO2014075157A1 PCT/BR2013/000459 BR2013000459W WO2014075157A1 WO 2014075157 A1 WO2014075157 A1 WO 2014075157A1 BR 2013000459 W BR2013000459 W BR 2013000459W WO 2014075157 A1 WO2014075157 A1 WO 2014075157A1
Authority
WO
WIPO (PCT)
Prior art keywords
coffee
oil
healing
composition according
composition
Prior art date
Application number
PCT/BR2013/000459
Other languages
French (fr)
Portuguese (pt)
Inventor
Comércio De Óleos Essenciais Ltda. Linax
Paulo Eduardo NEVES FERREIRA VELHO
Maia NILSON BORLINA
Lania BRUNO GROSSELLI
Original Assignee
Universidade Estadual De Campinas - Unicamp
Instituto Agronômico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Estadual De Campinas - Unicamp, Instituto Agronômico filed Critical Universidade Estadual De Campinas - Unicamp
Publication of WO2014075157A1 publication Critical patent/WO2014075157A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Definitions

  • the present invention relates to a coffee oil based composition. More specifically, the present invention relates to a topical use composition based on roasted coffee oil with skin healing ability. Furthermore, further objects are their use and a formulation comprising said composition.
  • the healing process can be more simply divided into three phases: inflammatory, proliferative and remodeling (Pittman, 2007).
  • inflammatory phase after hemostatic coagulation has begun, numerous chemical mediators are released by inflammatory cells.
  • the macrophage is the most important cell of this phase and will remain from the third to the tenth day.
  • Lymphocytes appear in the lesion approximately one week later.
  • the lymphokines released by them influence the action of macrophages (Mandelbaum, 2003). In addition to these, this phase relies on fibronectin.
  • the proliferation phase is responsible for the closure of the lesion itself. In it happens reepithelization by the migration of keratinocytes from the wound edges and attachments if they have been preserved (Dielgmann et al., 1981; Clark, 1985; Gentil Subscribe et al, 1999). Cytokines modulate the inflammatory process that is necessary in the healing process but can be harmful if excessive. They are also responsible for faster and more effective healing (Gentil Subscribe et al, 1999). Matrix formation depends, in addition to inflammatory and endothelial cells, on the fibroblast responsible for the production of substances important for both debridement and physiological remodeling (Van Winkle, 1967). The proliferation of vessels that occurs at this stage is essential for the supply of oxygen and nutrients for healing. Thus, it can be said that the proliferation phase is divided into reepithelization, fibroplasia and angiogenesis (Mandelbaum, 2003).
  • Remodeling is the last phase, lasting months and is responsible for increasing tensile strength and decreasing scar size.
  • Collagen reformulations, improvement in collagen fiber components, water resorption are events that allow for a connection that increases scar strength and decreases thickness (Doillon et al., 1985).
  • Local neovasculature decreases, and the normal healing area has about 80% of the normal tensile strength of the skin, is not bulky and is flat (Mandelbaum, 2003).
  • adiponectin adiponectin, leptin, interleukin (IL) 2, IL-4, IL-6, IL-12, tumor necrosis factor (TNF) ) -a, insulin-related growth factor (IGF) -1, interferon (IFN) -ae IFN- ⁇ .
  • IL interleukin
  • TNF tumor necrosis factor
  • IGF insulin-related growth factor
  • IFN interferon
  • Adiponectin is a protein that acts on glucose and lipid homeostasis. Circulating adiponectin levels are high, reaching approximately 0.01% of plasma proteins (Basu, 2009). It is induced during adipocyte differentiation and its secretion is stimulated by insulin. Adiponectin is an adipokine that influences systemic metabolism. It acts on glucose and fatty acid metabolism, being in some situations antagonistic to TNF- ⁇ (Yano, 2008). Induces a decrease in serum glucose and triglyceride levels, increases the level of glucagon.
  • adiponectin acts directly on keratinocytes, regulating the expression of immunomodulatory substances produced by these cells; This indicates that adiponectin acts indirectly on other cells through keratinocyte products. Another action would be the suppression of keratinocyte proliferation and differentiation, which would be beneficial in cases of hyperkeratinization (Kaway, 2008). A study conducted in Brazil indicates that overweight has the ability to increase healing time (Nascimento, 2006).
  • leptin Lack of leptin in animals as well as in humans can lead to weight gain and also to increased healing time. Direct administration of leptin leads to reduced healing time, with greater reepithelization, but without interfering with angiogenesis. Another fact observed in animals is the increased expression of leptin receptor genes locally, which indicates the importance of leptin for healing process. Leptin leads to an increase in application keratinocytes at the beginning of healing (Nascimento, 2006).
  • IL-2 is a pleiotropic cytokine (like most cytokines), ie it has multiple effects: a single cytokine can interact with more than one cell type, have multiple biological activities, interact with other cytokines with which it may have overlapping activities (Arai, 1990). Produced primarily by mitogenic or antigenically activated T lymphocytes. It has a key role in promoting clonal expansion of antigen-specific T cells. In addition, IL-2 is capable of mediating multiple immune responses in a variety of cell types.
  • IL-2 stimulates thymocyte proliferation, proliferation and differentiation of activated B cells; promotes monocyte growth and differentiation and cytocidal activity; induces the growth of natural killer cells and their production of cytokines and cytolytic activity; increases the production of lymphocyte-activated killer cells (LAK) and induces oligodendrocyte proliferation and differentiation (Goldsmith, 1994). In hypertrophic scarring and keloid situations, IL-2 is found in local lymphocytes, suggesting pro-scarring action (Armour, 2007).
  • IL-4 is also a pleiotropic cytokine that has multiple immune response modulation activities in a variety of cell types. It is a B cell activation / differentiation factor that regulates the isotope exchange of Ig, particularly IgG1 and IgE. It suppresses the development of IFN- ⁇ -producing CD4 + T cells and regulates the differentiation of naive helper T cells in the Th2 subset that mediates the allergic and humoral immune response.
  • TNF- ⁇ synergistically induces the expression of VCAM-1 (vascular cell adhesion molecule 1) in smooth endothelial and muscle cells, resulting in selective recruitment of eosinophils and lymphocytes at the inflammation site.
  • VCAM-1 vascular cell adhesion molecule 1
  • IL-4 negatively regulates the production of inflammatory mediators such as IL-, TNF- ⁇ , and prostaglandin 2 (PGE 2 ) in monocytes. Anti-tumor activity has been demonstrated both in vivo and in vitro.
  • the cells that secrete IL-4 are basophils, CD8 + T, memory CD4 + and naive Th2, mast cells, eosinophils, and virus-activated dendritic cells.
  • IL-4 is the -
  • tenascin an extracellular matrix glycoprotein, present as a thin layer in the adult papillary dermis, but which is restated in the healing process
  • fibroblasts in the earlier stages of collagen deposition and cell migration (Makhluf, 1996).
  • IL-6 is a cytokine that plays important roles in host defense, acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 is essential for the transition from acute inflammation. It is secreted by various cell types and production is regulated by numerous signals such as mitogenic or antigenic stimuli, lipopolysaccharides, calcium, other cytokines, and viruses. Cytokines IL-4, IL-10 and IL-13 inhibit IL-6 expression in monocytes (Hirano, 1996). Elevated IL-6 serologic levels were observed in pathological situations such as viral and bacterial infections, trauma, autoimmune diseases and inflammation.
  • IL-6 increases early in the healing process and is important because it has mitogenic properties in keratinocytes as well as chemotactic to neutrophils and their infiltration to the affected area has the ability to increase local angiogenesis and increase local collagen deposition. of the wound (Lin, 2003).
  • IL-12 is a heterodimeric glycoprotein that enhances cytotoxic activity and induces IFN- ⁇ production in the natural killer, T and T dendritic cells of the epidermis. It also induces IFN- ⁇ production in macrophages.
  • This cytokine together with others of the same family (IL-23 and IL-27), is capable of promoting the development of immune response through CD4 + Th1 T cells;
  • IL-12 promotes Th1 cell production after IL-27 has transformed ThO into Th0 / 1; Together with IL-18, IL-12 creates memory Th1 cells from effector cells (Hamza, 2010). In healing processes, IL-12 has increased gene expression, causing macrophages to produce and secrete more IFN- ⁇ (Ishida, 2004).
  • TNF- ⁇ plays critical roles in normal host resistance to infection and growth of malignant tumors, serving as immunostimulants and as mediators of the inflammatory response. A lot of TNF production, however, has been implicated as playing a role in a number of pathological conditions, including cachexia, septic shock, and autoimmune diseases. TNF- ⁇ is produced by activation of macrophages and other cell types, including T and B cells, NK cells, endothelial cells, smooth muscle cells, and some tumor cells. In healing, the absence of receptors for this cytokine accelerates the process (Ware, 1996). In wounds, TNF- ⁇ is responsible for initiating the proinflammatory cascade and is responsible for healing strength and tension (Mast, 1996).
  • GF-I also known as somatomedin C, is a member of the insulin superfamily. It has been found to mediate hormone actions in somatic cell growth, but it has also been shown to be an important regulator of cell metabolism, differentiation and survival. IGF-I is synthesized as a preprotein that is proteolytically cleaved to generate mature protein (Humbel, 1990). IGF-1, together with platelet-derived growth factor 2 (PDGF-2), can increase skin thickness in wound healing (Lynch, 1989), and this substance is directly involved in the regeneration of various tissue types. , not just the epithelial (Chen, 2010).
  • PDGF-2 platelet-derived growth factor 2
  • IFN-cf is a cytokine family glycoprotein that participates in cell control and replication, host defense against foreign organisms such as viruses or bacteria and is a major type I interferon. It is produced by mononuclear phagocytes in response to viral infection. It has a role in inhibiting viral replication and enhancing the expression of type I (MHC type I) main histocompatibility complex molecules, either by autocrine or paracrine activity (Krause, 2005). Another form of action of IFN- ⁇ is to protect some cells against virus entry. Numerous investigations have shown that IFN is involved in cell growth regulation and immunomodulatory effect (Ferrantini, 2007).
  • IFN- ⁇ also known as type II interferon
  • type II interferon was initially identified as a product with anti-viral activity of mitogenically activated T lymphocytes.
  • Some of the most important functions are macrophage effector function stimulation, IL-12 induced Th1 differentiation, modulation of MHC molecule class I and II expression, regulation of immunoglobulin (Ig) class exchange and regulation of interactions between leukocytes and endothelium.
  • IFN- ⁇ has also been involved in physiological roles in sensory neurons and spermatogenesis (Neumann, 1997; Kanzaki, 1998).
  • Both interferons have anti-scarring action, inhibiting collagen synthesis and cell proliferation and may increase the production of metalloproteinases.
  • IFN- ⁇ may increase the production of collagenase enzyme, which increases its anti-scarring action.
  • both must have their values increased in the final phase of healing, preventing it from progressing to hypertrophic injury (Tredget, 2000).
  • the claimed formulation has anti-inflammatory action, it cannot be stated that it could be applied effectively in the treatment of skin ulcers. This is because the healing process requires a balance between the production of inflammatory and anti-inflammatory substances and in this case, although in vitro studies may indicate some possibility of application of the product in an anti-inflammatory situation, for example, the final result in vivo may be completely different, and may even make it impossible to use it for the aforementioned application. In the healing process, the same substance can behearted.
  • green coffee or crude bean oil does not promote healing action in vivo, but only roasted coffee bean oil had comparable action to AGE. ®, based on medium chain essential fatty acids and sunflower oil, which was used as one of the study controls. This shows that it is not any essential fatty acid, nor any coffee oil that has healing action.
  • the same substance may be anti-inflammatory and have no pro-healing action and it is necessary to compare and inventive work to obtain a product whose action in vivo proves to be beneficial in the healing process as a whole.
  • oil extracted from green or raw coffee (Coffea arabica), where most research is related to the pharmaceutical and cosmetic sector
  • oil extracted from roasted coffee obtained directly by pressing beans, is best known for its use in food sector, mainly as candies, candies and truffles fillings, liqueur formulation, flavor enhancer in soluble coffee, ice coffee, cappuccinos, various desserts, ice cream, puddings, sweets and milk-based preparations.
  • candies candies
  • truffles fillings, liqueur formulation, flavor enhancer in soluble coffee, ice coffee, cappuccinos, various desserts, ice cream, puddings, sweets and milk-based preparations.
  • the present invention relates to a coffee oil based composition, including roasted coffee beans, for the treatment of skin ulcers.
  • the topical use of this composition influences the systemic production - and not only at the site of application - of healing-related substances, suggesting that its use has a beneficial systemic healing action.
  • the proposed composition has advantages in several respects.
  • the characteristics of an effective wound care product should include ease of removal and comfort for the patient, good value for money, keeping the healing area moist and dry and protected, ease of application and adaptability (conformation to different parts of the body).
  • Another differential of the process described here is related to the systemic action that the technology has, where the serum levels of some substances have been altered, as well as being able to accelerate the healing process in relation to the type of collagen deposited in the site, being more effective than others. products commonly used for this purpose.
  • the present invention is a coffee oil based topical composition with high skin healing ability. Furthermore, the present invention also relates to the use and formulation of said composition.
  • Figure 1 shows the unhealed area of wounds (%) over 10 days of treatment of Group 1 animals (Witness).
  • Figure 2 shows the unhealed wound area (%) over 10 days of treatment of Group 2 animals (AGE).
  • Figure 3 shows the unhealed wound area (%) over 10 days of treatment of Group 3 animals (Crude Coffee Oil),
  • Figure 4 shows the unhealed wound area (%) over 10 days of treatment of Group 3 animals (Roasted Coffee Oil).
  • Figure 5 presents a graph regarding cellularity on the control side of the 4 groups.
  • Figure 6 presents a graph regarding the cellularity on the treated side in the 4 groups.
  • Annex 1 exemplifies the appearance of injuries on the fourth day of treatment in one of the visual evaluations performed.
  • the present invention describes a topical healing coffee oil based composition.
  • the main examples of products which may be prepared from the composition object of the present invention are:
  • composition of the present invention comprises the following components:
  • composition of the present invention may further comprise optional components to provide some desirable feature not achieved with the aforementioned components such as emollient, humectant, chelating agent, thickening system, antioxidant component, preservative system, colorants and flavorings.
  • optional components such as emollient, humectant, chelating agent, thickening system, antioxidant component, preservative system, colorants and flavorings.
  • compositions of the present invention as well as other components optionally added in the formulation will be described in more detail below.
  • concentrations and components may vary.
  • Coffee used as an oil extraction raw material may be of any type of beverage market classification: soft, hard or rinded and of any type of grain size or sieve used for grain size separation.
  • the roasting required for the process is the same industrial roasting used for the production of grain intended for consumption as a beverage, capable of generating the substances that promote the aroma and flavor characteristic of the beverage made by infusion with hot water.
  • the oil extraction process can be either by cold compression as used in the work developed, or by extraction with simple or supercritical solvents.
  • Studies carried out for the embodiment of the present invention make it possible to ensure that the cold pressed oil of roasted Coffea arabica obtained healing action in vivo.
  • the coffee used as raw material was purchased directly from the producer and later sent for roasting and oil extraction. This procedure was necessary because the commercialization system and scale used by the roasters are much larger than the 12 bags volume needed to obtain the oils used in the tests performed.
  • the coffee offered in the normal market does not have control of lots purchased by roasters, do not guarantee the harvest of the product (post harvest time), requires a purchase of at least 20 bags. and do not guarantee or specify storage conditions. To have a control of these factors, it was decided to buy from the producer and later industrialization.
  • roasting of the coffee was done in a commercial roaster (Lilla®) with water cooling and forced ventilation for six bags to ensure a homogeneous raw material volume, without contamination of other batches processed previously or later in the industry's silos.
  • the roasting treatment used was the conventional one applied to the production of coffee for internal drink, with a yield of 0.79 of raw / roasted coffee, which resulted in a total of 285kg of roasted coffee for extraction of roasted coffee oil.
  • Oil extraction and filtration The coffee oil employed in the present invention can be obtained by pressing the beans. Both cold compression extraction as used in the work developed, such as extraction with simple or supercritical solvents, are potentially capable of producing material suitable for treatment, provided that both the oil with the appropriate fatty acid composition and the substances, for example those responsible for the characteristic aroma and taste, generated in the roasting process are obtained.
  • the oil added to a pharmacologically acceptable carrier at a concentration ranging from 0.001% to 99.999%, preferably 70% may be used as a healing agent.
  • the dosage of coffee oil to be used depends on many factors such as the causative agent, the age, weight and clinical condition of the patient as well as the experience and judgment of the physician or practitioner administering the therapy.
  • the effective amount of coffee oil is the one that provides patient improvement detectable by a qualified practitioner.
  • the dosage range varies with the compound used, the route of administration and the potency of the particular compound.
  • both types of coffee raw and roasted
  • the equipment used was an "Expeller” (Piratininga®) press adapted for extracting oil from both raw and roasted coffee beans.
  • the machine has been retrofitted to receive suitable stainless steel hoppers, collection trays and vessels to obtain oil for use in the experiment, without contamination of other raw materials or extracted oils, yet ensuring a quality product that can be repeated for later industrialization. .
  • the six coffee bags for each type of raw coffee and the six roasted coffee generated respectively 23 and 38kg of crude oil. This volume was compatible with the minimum required volume of 20kg to operate the press type filter.
  • the hand-closing horizontal filter press is specially designed for high pressure filtration and clear oil production. the separation of filter sludge with high content of non-saponifiable material of interest for use in treatments. Table 1 shows the yields of the extraction process performed.
  • the material processed in the extraction and filtering was packed in sealed glass bottles with identified samples that were sent for gamma sterilization testing to a company that uses 60 Co radioisotope emitter.
  • the different materials (oil and coffee grounds) raw and roasted) properly identified were submitted to doses 3; 5; 7; 10; 12 and 15 KGy.
  • Chromatographic conditions programmed column temperature, initial temperature 120 ° C / 2min, heating from 120 ° C to 220 ° C on a scale of 2.2 ° C / min and from 220 to 235 ° C on a scale of 1.5 ° C / min remaining in
  • carrier gas hydrogen at a flow rate of 1 mL / min; make-up gas, nitrogen at 30 mL / min; injector temperature, 270 ° C; detector temperature, 310 ° C; injection volume 1 ⁇ L.
  • Quantification was performed by area normalization and the results were expressed in g / 100g of sample.
  • Table 2 presents the data on the fatty acid composition of oils as a function of grain roasting and gamma ray treatments. No significant differences were observed as a function of the application of any of the gamma rays applied.
  • Table 2 Composition (%) of fatty acids in raw and roasted coffee oils5 subjected to different doses of gamma radiation for sterilization purposes.
  • Local absorption and effectiveness of the present invention may be enhanced by using as appropriate carrier an appropriate amount of medium chain essential fatty acids or other chemical compounds known to facilitate absorption and delivery of the active compounds of the present invention used as a carrier for the preparation.
  • coffee oil This will be the preferred carrier of the composition of the present invention by a suitable percentage (q.s.p.) to achieve 100% of the formula based on the total weight of the composition.
  • Still other pharmaceutically acceptable carriers may be used as saline and buffers.
  • composition of the present invention may further comprise optional components such as:
  • EDTA ethylenediaminetetraacetic acid
  • PH adjusting agent such as triethanolamine or inorganic hydroxides
  • Preservative such as parabens, organic acids, imidazolidinines, diazolidines, phenolic alcohols; - Emollient such as alcohols and fatty acids, esters, ethers, mono-, di- or triglycerides, natural or synthetic hydrocarbons or organic carbonates and combinations thereof.
  • Humectant such as glycols, preferably glycerin, propylene glycol, butylene glycol and combinations thereof.
  • Bacteriostatic agent such as methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride and the like.
  • Active ingredients such as antibiotics, anesthetics, pain killers and scaling.
  • Representative drugs within these classes include gentamicin, benzoyl peroxide, glucocorticoids, hydrocortisone, vitamin D3, methotrexate, cyclosporine, retinoids.
  • composition described in the present invention may be prepared employing any process known in the prior art.
  • Coffee oil extracted by pressing the beans may be mixed under sterile conditions with a pharmacologically acceptable carrier, and with any preservative, buffer or propellant as required.
  • Topical preparations can be made by combining coffee oil with conventional pharmaceutical diluents and commonly used carriers in dry, liquid, cream and aerosol topical formulations.
  • Ointments and creams may, for example, be formulated with an aqueous or lipid base with the addition of suitable thickening or gelling agents.
  • Ointments, creams, pastes and gels may also contain excipients such as vegetable and animal fats, oils, waxes, paraffins, starch, cellulose derivatives, talc, zinc oxide, silicones, polyethylene glycol, silicic acid among others.
  • Powders and sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or a mixture of these substances. Additionally, sprays may contain propellants such as chlorofluorohydrocarbon, butane and propane.
  • Example 1 In Vivo Testing For the tests we used isogenic rats of Rattus norvegicus albinus strain NTacUnib: SD (SpragueDawIey), with an average age of 7 weeks and weight between 220 to 270g. The experiment was approved by the Animal Research Ethics Committee of the State University of Campinas, according to Federal Law 6.638.
  • the animals were prepared to perform the wounds and began to receive daily treatments with the different types of oil, separated into "groups" as shown in Table 3 below. In each group of animals they were subdivided to be sacrificed on days 2, 4 and 10 after the first treatment application.
  • Table 3 schematically shows the distribution of wounds and treatments received by each group of animals.
  • the animal received the first application of the wound-specific product as stipulated in Table 3, which was covered with gauze on each side of the animal to prevent contamination of the different oils applied to the same animal.
  • the gauze was attached by micropore-type adhesive and reinforced with external adhesive.
  • the wounds were cleaned daily with saline, the treatments repeated with the respective oils and the bandages replaced until the day determined for the sacrifice.
  • the animals were not anesthetized so that there was no interference with hepatic metabolism, since all animals accepted all procedures without aggression and were tolerant to manipulation.
  • the back and each wound of each animal were photographed with camera and digital magnifying glass, respectively, for later evaluation.
  • the skin of the trichotomized areas of the dorsal region was excised to the fascia, separating the proximal halves, with two wounds on each side. side for 10% formal fixation until slide preparation for histopathological evaluation.
  • New biopsies with circular slides of the same diameter were made at the four points of the anterior biopsies in the caudal portion of the excised skin.
  • Each of the four dermis or skin fragments removed were immediately identified and placed in a container containing liquid nitrogen and cryopreserved at -80 ° C at the end of the experiment until preparation for the real time PCR of apoptosis-associated substances. .
  • G1 39 G2 0 G3 0 G4 0
  • Figures 1, 2, 3 and 4 respectively, show the curves of the second degree polynomial regression, of the percentage of unhealed wound area in the Group (control), Group 2 (AGE), Group 3 (Raw Coffee Oil) animals. ) and Group 4 (Roasted Coffee Oil).
  • X-axis shows the number of days of treatment and Y-axis the percentage of the unhealed area, considering that on day zero all injuries were in the same area (100%).
  • the red vertical bars represent when the average healing curve reached 75% wound and 25% healed and the black bars represent when 50% of the area was healed.
  • Figure 1 shows that 25% and 50% healing was achieved at 4.7 and 7.7 days after the start of treatment.
  • Parameter (a) of the first degree equations represents the maximum point of the second degree regressions and indicates the time required in days for the curve to reach zero value, ie the total wound healing. So the farther from zero, the lower the initial healing effect of the treatment. Thus, AGE treatment was found to have a better initial effect than all others.
  • Parameter (b) indicates the slope of the line, in the case with negative values, is the graphical representation of the area without healing. The more inclined, the faster the healing rate. The slope of the curves represents the accumulated effects over time, corroborating with clinical observations that animals treated with roasted coffee oil showed a significant improvement after the fourth day of treatment.
  • Table 8 summarizes the days required to achieve 25% and 50% initial wound healing and the second degree derivative of the curves. Since the numbers analyzed correspond to the percentage of the area without healing, the negative value of the second degree derivative of polynomial function represents the healing acceleration (% of healing divided by the time square) of each treatment. Table 8. Number of days for healing of 25% and 50% of the treated areas and value of the second degree derivative.
  • the Witness treatment followed by Raw Coffee Oil, AGE and Roasted Coffee Oil.
  • the preparation of slides for histological analysis was performed as follows: the proximal portion injuries were preserved initially in alcohol and later in formaldehyde in individual bottles properly identified for the preparation of slides for histological analysis. After extraction of each wound from a longitudinal section covering the entire remaining wound or scar, the piece was stained by the Hematoxylin and Eosin (HE) method and contained in paraffin block for microtome work and assembly of the referred blade.
  • HE Hematoxylin and Eosin
  • the blades were subjectively and objectively analyzed to estimate the wound healing rate blindly, that is, without the evaluators knowing the identification of the blade they were examining. 1) Subjective histological evaluation
  • Subjective histological evaluation was done blindly, that is, the dermatopathologist who participated in the project made the evaluation without knowing the identification of the slides she was examining.
  • cycloid there are 30 half circles. Each nucleus that touched one of the cycloids or half circles was counted. This is a comparative method that shows whether healing is developed (adult, composed of fibrocytes) or if it is still young (composed of fibroblasts). In the “adult phase” the number of nuclei is small; In the “young phase”, the number of nuclei is higher. Thus, if a sample has many nuclei, it can be said that the tissue is young (it is still at the beginning of the healing process).
  • the evaluated inflammatory cytokines have different actions on the healing process and some have more intense action in the early stages of healing. For this reason the dosages, besides the histological evaluation, were also made in the different healing phases: D2, inflammatory phase; D4, proliferative phase and D10, beginning of remodeling phase that extends for months.
  • the GAPD Rat gene (TaqMan TM - Applied Biosystems), Part number 4352338E, was chosen as the endogenous control of the reaction, which serves to normalize the expression of the gene of interest in the different samples.
  • the catheter GAPD is labeled with VIC fluorophore, while target primers are labeled with FAM fluorophore.
  • a scatter plot was constructed, which aims to define the range of concentrations for which the system is efficient.
  • the same logarithm values of the concentration of the samples on the X axis were used and the difference between the means of the endogenous control Cts and the means of the gene of interest for each concentration on the Y axis.
  • a trend line for these values was obtained, which has a line equation in which it is possible to verify the slope value of this line.
  • the slope value must be less than 0.1 (the closer this value is to zero, the smaller the slope of the curve is and, therefore, the more constant is the difference between the mean Cts of the gene of interest and the endogenous control).
  • the points on the graph corresponding to the concentrations that are closest to the trend line are considered validated (the system has 100% efficiency at these concentrations).
  • sample concentration validated as efficient for the adiponectin, leptin and GAPD genes was 40.0 ng cDNA.
  • Methods for Relative Quantification of Gene Expression allow quantifying differences in the level of expression of a specific gene (target) between different samples. Data production is expressed as a change or difference in the number of times in expression levels.
  • a sample was chosen as calibrator and an endogenous gene was also chosen to normalize the results. The standardized results obtained are always relative to the calibrator data.
  • the calibrator sample used for all groups presented the median value between the three measurements taken for each day of treatment (two, four or ten days).
  • adiponectin was tissue increased in D4 and D10 in group 3 when compared to the control group and increased in group 4 when compared to the contralateral side.
  • IGF-1 was increased on days 2 and 4 in group 3 when compared to the control group and both in group 3 and group 2 when compared to the contralateral side.
  • IL-6 presented better tissue results in group 3 and group 2 when compared to control and in group 3 and group 4 in D2 when compared to the contralateral side.
  • IFN-alpha showed better results in the early days (2 and 4) in group 2 and group 4 and, on day 10, in group 3 when compared to the control group. In comparison with the contralateral wound, group 2 presented better results.
  • IFN-gamma showed better results in groups 2 and 4 compared to control group and group 2 compared to contralateral wounds.
  • IL-12 which as IFN has anti-healing action, had lower levels in group 4 compared to control group and group 2 compared to contralateral wounds.
  • TNF-alpha and leptin showed better results in group 3 when compared to the control group.
  • Leptin was increased in group 2 compared to the contralateral wound.
  • IL-2 was increased in group 3 as compared to the control group and contralateral wounds. This cytokine was also increased in group 4 when compared to the control group. No significant variations were observed regarding IL-4.
  • This assay employs the quantitative sandwich immunoassay technique.
  • a target substance-specific monoclonal antibody is pre-added to a microplate at the factory.
  • Samples, controls and standards are pipetted into the wells and if the test substance is present it will be bound by the immobilized antibody.
  • a substance-specific enzyme-linked polyclonal antibody is added to the wells.
  • a substrate solution is added to the wells.
  • the reaction enzyme produces a blue product that turns yellow when the Stop Solution is added.
  • the color measurement intensity is in proportion to the amount of target substance bound in the initial step.
  • the sample values are then read from the standard curve.
  • the plates of the 5 kits were analyzed on the Bio Rad 680 Microplate Reader, BioRad Laboratories (Hercules, CA, USA) at 490 and 570nm wavelengths as recommended by the manufacturers.
  • the cytokines that favored healing in group 3 were the
  • IGF-1 INF-alpha
  • IL-12 IGF-1, INF-alpha and IL-12 (on day 10).
  • Adiponectin was systemically favorable for healing that occurred in group 2.
  • IL-12 was elevated in this group, acting favorably in the early days (2 and 4).
  • IL-4 was elevated in the group, favoring healing.
  • Example 5 Statistical interpretation of evaluations of inflammatory (Real-T ⁇ me PCR) and systemic (Elisa) scar tissue cytokines
  • PCR which evaluates the amount of cytokines in the tissue, it was possible to determine a statistically significant difference favorable to group 3 (raw coffee oil) when compared to the control group for cytokines: IGF-1 and leptin (only on day 4).
  • group 3 raw coffee oil
  • cytokines IGF-1 and leptin (only on day 4).
  • the cytokines found at levels favorable for healing in group 3 were INF-alpha and gamma and leptin (on day 4).
  • AGE favorably interfered with tissue production of IGF-, IFN-alpha and IL-12 when compared to the control group and ITN-alpha when compared to the contralateral wound.
  • Roasted coffee oil produced tissue healing action with significant statistical difference when dosing adiponectin and INF-gamma and the systemic dosage of adiponectin, IFN-alpha and gamma and IL-2 suggesting the relevance of these cytokines in the healing process.
  • This systemic effect signals a possible medicinal use of coffee oil, since many dermatoses and other diseases are related to the high production of TNF- ⁇ , for example as psoriasis and various rheumatological diseases. This systemic effect was particularly evident on the second day of the experiment.

Abstract

The present invention describes a composition and formulation thereof based on coffee oil, for topical use, with high skin wound healing capacity. The composition can keep ideal moisture conditions in the wound area and keep the peripheral zones dry and protected, besides exhibiting systemic action, which are all factors the accelerate the skin wound healing process.

Description

COMPOSIÇÃO E FORMULAÇÃO A BASE DE ÓLEO DE CAFÉ E USOS  COFFEE OIL BASED COMPOSITION AND FORMULATION AND USES
Campo da Invenção Field of the Invention
A presente invenção refere-se a uma composição a base de óleo de café. Mais especificamente, o presente invento trata de uma composição de uso tópico a base de óleo de café torrado com capacidade de cicatrização cutânea. Além disso, são objetos adicionais seu uso e uma formulação compreendendo a referida composição.  The present invention relates to a coffee oil based composition. More specifically, the present invention relates to a topical use composition based on roasted coffee oil with skin healing ability. Furthermore, further objects are their use and a formulation comprising said composition.
Fundamentos da Invenção  Background of the Invention
As tentativas humanas de intervir no processo da cicatrização de feridas, sejam elas acidentais ou intencionalmente promovidas durante procedimentos cirúrgicos, remontam à Antiguidade. A incidência e a prevalência de úlceras crónicas é extremamente alta repercutindo em elevados custos financeiros. Embora no Brasil não se encontre dados precisos, alguns trabalhos demonstram que há grande impacto psíquicossocial e económico da cronificação de feridas. Elas são a segunda causa de afastamento do trabalho no Brasil (Ereno, 2003).  Human attempts to intervene in the wound healing process, whether accidental or intentionally promoted during surgical procedures, date back to antiquity. The incidence and prevalence of chronic ulcers is extremely high, resulting in high financial costs. Although accurate data are not found in Brazil, some studies show that there is a major psychosocial and economic impact of wound chronification. They are the second cause of absence from work in Brazil (Ereno, 2003).
Muitas variáveis tanto de ordem geral como de ordem local influenciam esse longo e complexo processo. Dos fatores gerais, interferem a idade, o estado nutricional do paciente, a existência de doenças de base, como diabetes, alterações cardiocirculatórias e de coagulação, aterosclerose, disfunção renal, quadros infecciosos sistémicos e uso de drogas sistémicas. Many general and local variables influence this long and complex process. Among the general factors, age, nutritional status, underlying diseases such as diabetes, cardiocirculatory and coagulation disorders, atherosclerosis, renal dysfunction, systemic infectious conditions and systemic drug use interfere.
Além deles, interferem também a localização anatómica da lesão, ráça, técnica cirúrgica utilizada, etc (Mandelbaum, 2003). In addition, they also interfere with the anatomical location of the lesion, race, surgical technique used, etc. (Mandelbaum, 2003).
Para que uma úlcera cutânea apresente cicatrização, ocorre, a nível celular e molecular, uma cascata de eventos que trabalham em conjunto para a repavimentação e reconstituição do tecido lesado (Ortonne, 1994).  For a skin ulcer to heal, a cascade of events occurs at the cellular and molecular levels that work together for the repaving and reconstitution of the injured tissue (Ortonne, 1994).
O processo de cicatrização pode ser dividido de forma mais simples em três fases: inflamatória, proliferativa e de remodelação (Pittman, 2007). Na fase inflamatória, depois de iniciada a coagulação hemostática, inúmeros mediadores químicos são liberados por células inflamatórias. Nos três primeiros dias, predomina a ação dos polimortonucleares, responsáveis pela fagocitose de bactérias. O macrófago é a célula mais importante desta fase e permanecerá do terceiro ao décimo dia. Os linfócitos aparecem na lesão aproximadamente com uma semana. As linfocinas por eles liberadas têm influência na ação dos macrófagos (Mandelbaum, 2003). Além destas, esta fase conta com a fibronectina. Sintetizada por fibroblastos, queratinócitos e células endoteliais, ela adere simultaneamente à fibrina, ao colágeno e a outros tipos de células, funcionando assim como cola para consolidar o coágulo de fibrina, as células e os componentes de matriz (Mosher, 1981). The healing process can be more simply divided into three phases: inflammatory, proliferative and remodeling (Pittman, 2007). In the inflammatory phase, after hemostatic coagulation has begun, numerous chemical mediators are released by inflammatory cells. We first three days, the action of polymortonuclear cells responsible for phagocytosis of bacteria predominates. The macrophage is the most important cell of this phase and will remain from the third to the tenth day. Lymphocytes appear in the lesion approximately one week later. The lymphokines released by them influence the action of macrophages (Mandelbaum, 2003). In addition to these, this phase relies on fibronectin. Synthesized by fibroblasts, keratinocytes, and endothelial cells, it adheres simultaneously to fibrin, collagen, and other cell types, thus acting as a glue to consolidate fibrin clot, cells, and matrix components (Mosher, 1981).
A fase de proliferação é responsável pelo fechamento propriamente dito da lesão. Nela acontece a reepitelização pela migração dos queratinócitos a partir das bordas da ferida e dos anexos, se estes foram preservados (Dielgmann et al., 1981 ; Clark, 1985; Gentilhomme et al, 1999). As citocinas modulam o processo inflamatório que é necessário no processo cicatricial, mas que pode ser prejudicial se excessivo. Elas também são responsáveis por uma cicatrização mais rápida e eficaz (Gentilhomme et al, 1999). A formação da matriz depende, além das células inflamatórias e endoteliais, do fibroblasto responsável pela produção de substâncias importantes tanto para o desbridamento como para a remodelação fisiológica (Van Winkle, 1967). A proliferação de vasos que ocorre nesta fase é essencial para o suprimento de oxigénio e nutrientes para a cicatrização. Desta forma, pode-se dizer que a fase de proliferação é dividida em reepitelização, fibroplasia e angiogênese (Mandelbaum, 2003).  The proliferation phase is responsible for the closure of the lesion itself. In it happens reepithelization by the migration of keratinocytes from the wound edges and attachments if they have been preserved (Dielgmann et al., 1981; Clark, 1985; Gentilhomme et al, 1999). Cytokines modulate the inflammatory process that is necessary in the healing process but can be harmful if excessive. They are also responsible for faster and more effective healing (Gentilhomme et al, 1999). Matrix formation depends, in addition to inflammatory and endothelial cells, on the fibroblast responsible for the production of substances important for both debridement and physiological remodeling (Van Winkle, 1967). The proliferation of vessels that occurs at this stage is essential for the supply of oxygen and nutrients for healing. Thus, it can be said that the proliferation phase is divided into reepithelization, fibroplasia and angiogenesis (Mandelbaum, 2003).
A remodelação é a última fase, dura meses e é responsável pelo aumento da força de tensão e diminuição do tamanho da cicatriz. Reformulações dos colágenos, melhoria nos componentes das fibras colágenas, reabsorção de água são eventos que permitem uma conexão que aumenta a força da cicatriz e diminui sua espessura (Doillon et al., 1985). A neovasculatura local diminui, e a área cicatricial normal tem cerca de 80% da força de tensão da pele normal, não é volumosa e é plana (Mandelbaum, 2003). Dentre as substâncias relacionadas com a inflamação que acredita-se interferirem no processo cicatricial, destacam-se as seguintes: adiponectina, leptina, interleucina (IL) 2, IL-4, IL-6, IL-12, fator de necrose tumoral (TNF)-a, fator de crescimento relacionado à insulina (IGF)-1 , interferon (IFN)-a e IFN-γ. Remodeling is the last phase, lasting months and is responsible for increasing tensile strength and decreasing scar size. Collagen reformulations, improvement in collagen fiber components, water resorption are events that allow for a connection that increases scar strength and decreases thickness (Doillon et al., 1985). Local neovasculature decreases, and the normal healing area has about 80% of the normal tensile strength of the skin, is not bulky and is flat (Mandelbaum, 2003). Among the inflammation-related substances believed to interfere with the healing process, the following stand out: adiponectin, leptin, interleukin (IL) 2, IL-4, IL-6, IL-12, tumor necrosis factor (TNF) ) -a, insulin-related growth factor (IGF) -1, interferon (IFN) -ae IFN-γ.
A adiponectina uma proteína que atua na homeostase de glicose e lipídeos. Os níveis de adiponectina circulante são altos, chegando a aproximadamente 0,01% das proteínas plasmáticas (Basu, 2009). É induzida durante a diferenciação do adipócito e sua secreção é estimulada por insulina. A adiponectina é uma adipocina que influência o metabolismo sistémico. Atua no metabolismo de glicose e ácidos graxos, sendo em algumas situações antagonista ao TNF-α (Yano, 2008). Induz uma diminuição nos níveis séricos de glicose e triglicérides, aumenta o nível de glucagon. No fígado promove a inibição insulina-dependente da gliconeogenese e tem ação antifibrosante; no músculo esquelético promove o uso e oxidação de ácidos graxos, uso de glicose e produção de lactato. Age como anti-inflamatório e tem ação protetora contra a aterosclerose (Berg, 2001 ). Na pele de pacientes diabéticos, a adiponectina atua diretamente nos queratinócitos, regulando a expressão de substâncias imunomoduladoras produzidas por estas células; isso indica que a adiponectina atua indiretamente sobre outras células, através dos produtos dos queratinócitos. Outra ação seria a supressão da proliferação e diferenciação dos queratinócitos, o que seria benéfico em casos de hiperqueratinização (Kaway, 2008). Estudo realizado no Brasil aponta que o sobrepeso tem a capacidade de aumentar o tempo de cicatrização (Nascimento, 2006).  Adiponectin is a protein that acts on glucose and lipid homeostasis. Circulating adiponectin levels are high, reaching approximately 0.01% of plasma proteins (Basu, 2009). It is induced during adipocyte differentiation and its secretion is stimulated by insulin. Adiponectin is an adipokine that influences systemic metabolism. It acts on glucose and fatty acid metabolism, being in some situations antagonistic to TNF-α (Yano, 2008). Induces a decrease in serum glucose and triglyceride levels, increases the level of glucagon. In the liver it promotes insulin-dependent inhibition of gluconeogenesis and has anti-fibrous action; In skeletal muscle it promotes the use and oxidation of fatty acids, glucose use and lactate production. Acts as anti-inflammatory and has protective action against atherosclerosis (Berg, 2001). In the skin of diabetic patients, adiponectin acts directly on keratinocytes, regulating the expression of immunomodulatory substances produced by these cells; This indicates that adiponectin acts indirectly on other cells through keratinocyte products. Another action would be the suppression of keratinocyte proliferation and differentiation, which would be beneficial in cases of hyperkeratinization (Kaway, 2008). A study conducted in Brazil indicates that overweight has the ability to increase healing time (Nascimento, 2006).
A falta de leptina nos animais, assim como nos humanos, pode levar a um aumento de peso e também ao aumento no tempo necessário para cicatrização. A administração direta de leptina leva a diminuição do tempo de cicatrização, com maior reepitelização, mas sem interferir na angiogênese. Outro fato observado em animais é do aumento da expressão de genes de receptores para leptina localmente, o que indica a importância da leptina para o processo cicatricial. A leptina leva a um aumento dos queratinocitos no local de aplicação, no início da cicatrização (Nascimento, 2006). Lack of leptin in animals as well as in humans can lead to weight gain and also to increased healing time. Direct administration of leptin leads to reduced healing time, with greater reepithelization, but without interfering with angiogenesis. Another fact observed in animals is the increased expression of leptin receptor genes locally, which indicates the importance of leptin for healing process. Leptin leads to an increase in application keratinocytes at the beginning of healing (Nascimento, 2006).
A IL-2 é uma citocina pleiotrópica (assim como a maioria das citocinas), isto é, têm múltiplos efeitos: uma única citocina pode interagir com mais de um tipo de célula, ter múltiplas atividades biológicas, interagir com outras citocinas, com as quais pode ter sobreposição de atividades (Arai, 1990). Produzida primariamente por linfócitos T ativados mitogênica ou antigenicamente. Possui papel chave na promoção da expansão clonal de células T antígeno-específicas. Além disso, a IL-2 é capaz de mediar múltiplas respostas imunes numa variedade de tipos celulares. A IL-2 estimula a proliferação dos timócitos, a proliferação e diferenciação de células B ativadas; promove o crescimento e diferenciação e a atividade citocida dos monócitos; induz o crescimento das células natural killer e a produção nelas de citocinas e da ativida citolítica; aumenta a produção de células LAK (células killer ativadas por linfócito) e induz a proliferação e diferenciação de oligodendrócitos (Goldsmith, 1994). Em situações de cicatriz hipertrófica e quelóides o IL-2 é encontrado em linfócitos locais, sugerindo ação pró-cicatricial (Armour, 2007).  IL-2 is a pleiotropic cytokine (like most cytokines), ie it has multiple effects: a single cytokine can interact with more than one cell type, have multiple biological activities, interact with other cytokines with which it may have overlapping activities (Arai, 1990). Produced primarily by mitogenic or antigenically activated T lymphocytes. It has a key role in promoting clonal expansion of antigen-specific T cells. In addition, IL-2 is capable of mediating multiple immune responses in a variety of cell types. IL-2 stimulates thymocyte proliferation, proliferation and differentiation of activated B cells; promotes monocyte growth and differentiation and cytocidal activity; induces the growth of natural killer cells and their production of cytokines and cytolytic activity; increases the production of lymphocyte-activated killer cells (LAK) and induces oligodendrocyte proliferation and differentiation (Goldsmith, 1994). In hypertrophic scarring and keloid situations, IL-2 is found in local lymphocytes, suggesting pro-scarring action (Armour, 2007).
A IL-4 também é uma citocina pleiotrópica que possui múltiplas atividades de modulação de resposta imune numa variedade de tipos celulares. É um fator de ativação/diferenciação das células B, que regula a troca de isótopo do Ig, particularmente lgG1 e IgE. Ela suprime o desenvolvimento de células T CD4+ produtoras de IFN-γ e regula a diferenciação de células T helper naive no subconjunto Th2 que media a resposta alérgica e humoral imune. Junto com o TNF-α induz sinergicamente a expressão de VCAM-1 (molécula de adesão à célula vascular 1) em células endoteliais e musculares lisas, resultando no recrutamento seletivo de eosinófilos e linfócitos no sítio de inflamação. A IL-4 regula negativamente a produção de mediadores inflamatórios como a IL- , TNF-α, e prostaglandina 2 (PGE2) em monócitos. Foi demonstrado atividade anti-tumoral tanto in vivo quanto in vitro. As células que secretam IL-4 são os basófilos, T CD8+, CD4+ de memória e Th2 naive, mastócitos, eosinófilos e células dendríticas ativadas por vírus. A IL-4 é a - IL-4 is also a pleiotropic cytokine that has multiple immune response modulation activities in a variety of cell types. It is a B cell activation / differentiation factor that regulates the isotope exchange of Ig, particularly IgG1 and IgE. It suppresses the development of IFN-γ-producing CD4 + T cells and regulates the differentiation of naive helper T cells in the Th2 subset that mediates the allergic and humoral immune response. Along with TNF-α synergistically induces the expression of VCAM-1 (vascular cell adhesion molecule 1) in smooth endothelial and muscle cells, resulting in selective recruitment of eosinophils and lymphocytes at the inflammation site. IL-4 negatively regulates the production of inflammatory mediators such as IL-, TNF-α, and prostaglandin 2 (PGE 2 ) in monocytes. Anti-tumor activity has been demonstrated both in vivo and in vitro. The cells that secrete IL-4 are basophils, CD8 + T, memory CD4 + and naive Th2, mast cells, eosinophils, and virus-activated dendritic cells. IL-4 is the -
principal responsável por estimular a produção de tenascina (uma glicoproteína da matriz extracelular, presente como uma fina camada na derme papilar adulta, mas que é reexpressa no processo cicatricial) por fibroblastos, nas fases anteriores da deposição de colágeno e migração celular (Makhluf, 1996). primarily responsible for stimulating the production of tenascin (an extracellular matrix glycoprotein, present as a thin layer in the adult papillary dermis, but which is restated in the healing process) by fibroblasts in the earlier stages of collagen deposition and cell migration (Makhluf, 1996). ).
A IL-6 é uma cítocína que desempenha papéis importantes na defesa do hospedeiro, em reações de fase aguda, inflamação, hematopoiese, metabolismo ósseo, e progressão do câncer. A IL-6 é essencial para a transição de inflamação aguda. Ela é secretada por vários tipos de células e a produção é regulada por numerosos sinais como estímulos mitogênicos ou antigênicos, lipopolisacarídeos, cálcio, outras citocinas e vírus. As citocinas IL- 4, IL-10 e IL-13 inibem a expressão de IL-6 nos monócitos (Hirano, 1996). Níveis sorológicos elevados de IL-6 foram observados em situações patológicas como infecções virais e bacterianas, trauma, doenças autoimunes e inflamação. A IL-6 aumenta no início do processo cicatricial e é importante, pois possui propriedade mitogênicas nos queratinóctios, assim como quimiotático para neutrófilos e a infiltração destes até a área afetada, tem capacidade de aumentar a angiogênese local e aumenta a deposição de colágeno no local da ferida (Lin, 2003).  IL-6 is a cytokine that plays important roles in host defense, acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 is essential for the transition from acute inflammation. It is secreted by various cell types and production is regulated by numerous signals such as mitogenic or antigenic stimuli, lipopolysaccharides, calcium, other cytokines, and viruses. Cytokines IL-4, IL-10 and IL-13 inhibit IL-6 expression in monocytes (Hirano, 1996). Elevated IL-6 serologic levels were observed in pathological situations such as viral and bacterial infections, trauma, autoimmune diseases and inflammation. IL-6 increases early in the healing process and is important because it has mitogenic properties in keratinocytes as well as chemotactic to neutrophils and their infiltration to the affected area has the ability to increase local angiogenesis and increase local collagen deposition. of the wound (Lin, 2003).
A IL-12 é uma glicoproteína heterodimérica, que aumenta a atividade citotóxica e induz a produção de IFN-γ nas células natural killer, T e T dendríticas da epiderme. Também induz a produção de IFN-γ nos macrófagos. Esta citocina, em conjunto com outras da mesma família (IL-23 e IL-27), é capaz de promover o desenvolvimento de resposta imune através de células T CD4+ Th1 ; em resposta a infecções, a IL-12 promove a produção de células Th1 , após a IL-27 ter transformado o ThO em Th0/1 ; junto com a IL-18, a IL-12 cria células Th1 de memória a partir de células efetoras (Hamza, 2010). Em processos cicatríciais, a IL-12 tem sua expressão genética aumentada, fazendo com que os macrófagos produzam e secretem mais IFN-y (lshida, 2004).  IL-12 is a heterodimeric glycoprotein that enhances cytotoxic activity and induces IFN-γ production in the natural killer, T and T dendritic cells of the epidermis. It also induces IFN-γ production in macrophages. This cytokine, together with others of the same family (IL-23 and IL-27), is capable of promoting the development of immune response through CD4 + Th1 T cells; In response to infections, IL-12 promotes Th1 cell production after IL-27 has transformed ThO into Th0 / 1; Together with IL-18, IL-12 creates memory Th1 cells from effector cells (Hamza, 2010). In healing processes, IL-12 has increased gene expression, causing macrophages to produce and secrete more IFN-γ (Ishida, 2004).
O TNF-α desempenha papéis críticos na resistência normal do hospedeiro à infecção e ao crescimento de tumores malignos, servindo como imunoestimulantes e como mediadores da resposta inflamatória. Excesso de produção de TNF, no entanto, tem sido implicada como desempenhando um papel numa série de condições patológicas, incluindo caquexia, choque séptico, e doenças auto-imunes. O TNF-α é produzido por ativação dos macrófagos e outros tipos de células, incluindo células T e B, células NK, células endoteliaís, células musculares lisas e algumas células tumorais. Na cicatrização a ausência de receptores para esta citocina acelera o processo (Ware, 1996). Em feridas, o TNF- α é um dos responsáveis por iniciar a cascata pró-inflamatória, sendo responsável pela força e tensão cicatricial (Mast, 1996). TNF-α plays critical roles in normal host resistance to infection and growth of malignant tumors, serving as immunostimulants and as mediators of the inflammatory response. A lot of TNF production, however, has been implicated as playing a role in a number of pathological conditions, including cachexia, septic shock, and autoimmune diseases. TNF-α is produced by activation of macrophages and other cell types, including T and B cells, NK cells, endothelial cells, smooth muscle cells, and some tumor cells. In healing, the absence of receptors for this cytokine accelerates the process (Ware, 1996). In wounds, TNF-α is responsible for initiating the proinflammatory cascade and is responsible for healing strength and tension (Mast, 1996).
O !GF-I, também conhecido como somatomedína C, é um membro da superfamília insulina. Foi descoberto como um mediador de ações do hormônio no crescimento de células somáticas, mas também tem sido demonstrado ser um importante regulador do metabolismo celular, diferenciação e sobrevivência. IGF-I é sintetizado como uma pré-proteína que é proteoliticamente clivada para gerar a proteína madura (Humbel, 1990). O IGF- 1 , juntamente com o fator de crescimento derivado de plaquetas 2 (PDGF-2) , pode aumentar a espessura da pele na cicatrização de feridas (Lynch, 1989), e esta substância está diretamente envolvida na regeneração de vários tipos de tecidos, não apenas o epitelial (Chen, 2010).  ! GF-I, also known as somatomedin C, is a member of the insulin superfamily. It has been found to mediate hormone actions in somatic cell growth, but it has also been shown to be an important regulator of cell metabolism, differentiation and survival. IGF-I is synthesized as a preprotein that is proteolytically cleaved to generate mature protein (Humbel, 1990). IGF-1, together with platelet-derived growth factor 2 (PDGF-2), can increase skin thickness in wound healing (Lynch, 1989), and this substance is directly involved in the regeneration of various tissue types. , not just the epithelial (Chen, 2010).
O IFN-cf é uma glicoproteína pertencente à família das citocinas que participa no controle e na replicação celular, na defesa do hospedeiro contra organismos estranhos, como vírus ou bactérias e é um dos principais interferons de tipo I. É produzido por fagócitos mononucleares em resposta à infecção virai. Tem papel na inibição da replicação virai e aumenta a expressão de moléculas do complexo principal de histocompatibilidade do tipo I (MHC tipo I), seja por atuação autócrina ou parácrina (Krause, 2005). Outra forma de ação do IFN-α é proteger algumas células contra a entrada de vírus. Numerosas investigações mostraram que o IFN está envolvido na regulação do crescimento celular e no efeito imunomodulatório (Ferrantini, 2007).  IFN-cf is a cytokine family glycoprotein that participates in cell control and replication, host defense against foreign organisms such as viruses or bacteria and is a major type I interferon. It is produced by mononuclear phagocytes in response to viral infection. It has a role in inhibiting viral replication and enhancing the expression of type I (MHC type I) main histocompatibility complex molecules, either by autocrine or paracrine activity (Krause, 2005). Another form of action of IFN-α is to protect some cells against virus entry. Numerous investigations have shown that IFN is involved in cell growth regulation and immunomodulatory effect (Ferrantini, 2007).
O IFN-γ, também conhecido como interferon do tipo II, foi inicialmente identificado como produto com atividade anti-viral de linfócitos T ativados mitogenicamente. Possui papel chave na defesa do hospedeiro exercendo atividades imunoregulatórias, anti-proliferativas e pró-inflamatórias (Boehm, 1997). Algumas das funções mais importantes são a estimulação de funções efetoras dos macrófagos, aumento da diferenciação de Th1 induzido por IL-12, modulação da expressão das classes I e II de moléculas do MHC, regulação da troca de classe de imunoglobulinas (Ig) e regulação das interações entre leucócitos e endotélio. O IFN-γ também foi envolvido em papéis fisiológicos em neurónios sensores e na espermatogênese (Neumann, 1997; Kanzaki, 1998). IFN-γ, also known as type II interferon, was initially identified as a product with anti-viral activity of mitogenically activated T lymphocytes. Has a key role in host defense performing immunoregulatory, antiproliferative, and proinflammatory activities (Boehm, 1997). Some of the most important functions are macrophage effector function stimulation, IL-12 induced Th1 differentiation, modulation of MHC molecule class I and II expression, regulation of immunoglobulin (Ig) class exchange and regulation of interactions between leukocytes and endothelium. IFN-γ has also been involved in physiological roles in sensory neurons and spermatogenesis (Neumann, 1997; Kanzaki, 1998).
Ambos os interferons possuem ação anticicatricial, atuando na inibição da síntese de colágeno e proliferação celular e podem aumentar a produção de metaloproteinases. O IFN-α pode aumentar a produção da enzima colagenase, o que aumenta sua ação anticicatricial. Deste modo, ambas devem ter seus valores aumentados na fase final da cicatrização, impedindo que a mesma evolua para lesão hipertrófica (Tredget, 2000)  Both interferons have anti-scarring action, inhibiting collagen synthesis and cell proliferation and may increase the production of metalloproteinases. IFN-α may increase the production of collagenase enzyme, which increases its anti-scarring action. Thus, both must have their values increased in the final phase of healing, preventing it from progressing to hypertrophic injury (Tredget, 2000).
Estudos têm sido realizados avaliando o potencial do uso de produtos naturais como princípio ativos de recursos para cicatrização. Entre estes, foram realizados estudos com dendezeiro (Sasidharan, 2012), água termal (Faga, 2011 ), babosa (Duansak, 2003), Jatyadi Taila (Shailajan, 2011 ), hortelã (Takayama, 2011 ) e alguns tipos de óleo, tais como óleo de pinha (Tumen, 2011 ), óleo de arroz (BR 10 2012 028235 6). Especificamente no que se refere ao uso de óleos, já é conhecido do Estado da Arte, por exemplo, que àqueles ricos em ácidos graxos essenciais tem ações antissépticas e cicatrizantes.  Studies have been conducted evaluating the potential of using natural products as an active ingredient in healing resources. Among these, studies were carried out with oil palm (Sasidharan, 2012), thermal water (Faga, 2011), aloe (Duansak, 2003), Jatyadi Taila (Shailajan, 2011), mint (Takayama, 2011) and some types of oil such as like pine oil (Tumen, 2011), rice oil (BR 10 2012 028235 6). Specifically with regard to the use of oils, it is already known from the State of the Art, for example, that those rich in essential fatty acids have antiseptic and healing actions.
A cicatrização é um processo dinâmico e, portanto nenhum efeito antisséptico ou cicatrizante observado in vitro garante um resultado favorável in vivo. Por exemplo o álcool, sabidamente antisséptico, não é usado para cicatrização. A composição dos ácidos graxos não é alterada substancialmente pelo processo de aquecimento da torra dos grãos de café, por exemplo, contudo são gerados nesse processo compostos responsáveis pelo aroma e sabor característicos da bebida. Da mesma forma que estas substâncias novas podem mudar o aroma e sabor da infusão do pó de café em água quente, elas podem potencialmente estar envolvidas em uma resposta diferente do óleo de café no processo cicatricial. Healing is a dynamic process and therefore no antiseptic or healing effect observed in vitro guarantees a favorable outcome in vivo. For example, alcohol, known to be antiseptic, is not used for healing. The fatty acid composition is not substantially altered by the process of heating the roasting of coffee beans, for example, however, compounds responsible for the characteristic aroma and taste of the beverage are generated in this process. Just as these new substances can change the aroma and taste of the coffee powder infusion in hot water, they can may potentially be involved in a different response than coffee oil in the healing process.
Segundo recente artigo de revisão de Ferreira et al, publicado em 2012 na Revista da Escola de Enfermagem da USP, diante da escassez de estudos clínicos randomízados controlados em humanos não se pôde generalizar, na prática clínica, que os ácidos graxos essenciais influenciam positivamente no processo de cicatrização ou que possuem ação antimicrobiana. Assim, há necessidade de realização de pesquisas com maior rigor metodológico comparando as diferentes fórmulas disponíveis contendo ácidos graxo.  According to a recent review article by Ferreira et al, published in 2012 in the Journal of the School of Nursing of USP, in view of the scarcity of randomized controlled trials in humans, it was not possible to generalize in clinical practice that essential fatty acids positively influence the process. of healing or that have antimicrobial action. Thus, there is a need to conduct research with greater methodological rigor comparing the different available formulas containing fatty acids.
O documento BRPI0602842-A de 20/07/2006, por exemplo, descreve o uso de óleo de café verde (Coffea arábica) em formulações cosméticas e farmacêuticas para a manutenção das propriedades da pele, onde o referido óleo atua como agente propiciador de atividades de regeneração; firmeza e hidratação da pele; antioxidante; anti-radicais livres; anti-envelhecimento; redutor das rugosidades da pele; agente auxiliar na redução e prevenção de estrias; agente lipolítico; e agente anti-inflamatório, sendo que essas ações benéficas são obtidas com o óleo de café em sua forma bruta; semi-refinado, refinado, fracionado, hidrogenado ou interesterificado puro ou ainda em misturas com outros óleos e/ou ingredientes em preparações de produtos cosméticos e farmacêuticos, cujo resultado prático confere à pele características saudáveis.  Document BRPI0602842-A of 07/20/2006, for example, describes the use of green coffee oil (Coffea arabica) in cosmetic and pharmaceutical formulations for the maintenance of skin properties, where said oil acts as an activity promoting agent. of regeneration; firmness and hydration of the skin; antioxidant; free radicals; anti aging; skin roughness reducer; auxiliary agent in reducing and preventing stretch marks; lipolytic agent; and anti-inflammatory agent, and these beneficial actions are obtained with coffee oil in its crude form; semi-refined, refined, fractionated, hydrogenated or interesterified pure or in mixtures with other oils and / or ingredients in preparations of cosmetic and pharmaceutical products, whose practical result gives the skin healthy characteristics.
Contudo, embora a formulação reivindicada tenha ação antiinflamatória não se pode afirmar que a mesma poderia ser aplicada, com eficiência, no tratamento de úlceras cutâneas. Isso porque o processo cicatricial exige um equilíbrio entre a produção de substâncias inflamatórias e antiinflamatórias e, neste caso, embora estudos in vitro possam indicar alguma possibilidade de aplicação do produto em uma situação anti-inflamatória, por exemplo, o resultado final in vivo pode ser completamente diferente, podendo inviabilizar, inclusive, o seu uso para a referida aplicação vislumbrada anteriormente. No processo cicatricial, uma mesma substância pode ser „ However, although the claimed formulation has anti-inflammatory action, it cannot be stated that it could be applied effectively in the treatment of skin ulcers. This is because the healing process requires a balance between the production of inflammatory and anti-inflammatory substances and in this case, although in vitro studies may indicate some possibility of application of the product in an anti-inflammatory situation, for example, the final result in vivo may be completely different, and may even make it impossible to use it for the aforementioned application. In the healing process, the same substance can be „
necessária em concentrações mais altas no início do processo e em doses mais baixas no final do dito processo para evitar, por exemplo, uma cicatriz hipertrófica. needed at higher concentrations at the beginning of the process and at lower doses at the end of the process to avoid, for example, a hypertrophic scar.
Como ficará evidente nos resultados dos estudos realizados para a concretização da presente invenção, o óleo de café verde ou produzido a partir de grãos crus não promove uma ação cicatrizante in vivo, mas apenas o óleo obtido de grãos torrados de café tiveram ação comparável ao AGE®, a base de ácidos graxos essenciais de cadeias médias e óleo de girassol, e que foi utilizado como um dos controles do estudo. Isso mostra que não é qualquer ácido graxo essencial, nem qualquer óleo de café que tem a ação cicatrizante.  As will be apparent from the results of the studies carried out for the embodiment of the present invention, green coffee or crude bean oil does not promote healing action in vivo, but only roasted coffee bean oil had comparable action to AGE. ®, based on medium chain essential fatty acids and sunflower oil, which was used as one of the study controls. This shows that it is not any essential fatty acid, nor any coffee oil that has healing action.
Assim, um mesma substância pode ser anti-inflamatória e não ter ação pró-cicatricial e é necessária a comparação e trabalho inventivo para obter-se um produto cuja ação in vivo se mostre benéfica no processo cicatricial como um todo.  Thus, the same substance may be anti-inflammatory and have no pro-healing action and it is necessary to compare and inventive work to obtain a product whose action in vivo proves to be beneficial in the healing process as a whole.
Diferente do óleo extraído do café verde ou cru {Coffea arábica), em que a maioria das pesquisas está relacionada com o setor farmacêutico e cosmético, o óleo extraído do café torrado, obtido diretamente pela prensagem dos grãos, é mais conhecido por sua utilização no setor alimentício, principalmente como recheios de balas, bombons e trufas, formulação de licores, realçador do sabor em café solúvel, ice coffee, cappuccinos, sobremesas diversas, sorvetes, pudins, doces e preparados à base de leite. Não existem estudos prévios que avaliem a ação do óleo de café verde ou do óleo de café torrado sobre a cicatrização e a ação anti-inflamatória do óleo de café cru foi avaliada, sobretudo, em estudos in vitro.  Unlike oil extracted from green or raw coffee (Coffea arabica), where most research is related to the pharmaceutical and cosmetic sector, oil extracted from roasted coffee, obtained directly by pressing beans, is best known for its use in food sector, mainly as candies, candies and truffles fillings, liqueur formulation, flavor enhancer in soluble coffee, ice coffee, cappuccinos, various desserts, ice cream, puddings, sweets and milk-based preparations. There are no previous studies evaluating the action of green coffee oil or roasted coffee oil on healing and the anti-inflammatory action of raw coffee oil has been evaluated mainly in in vitro studies.
Estudo de Wagemaler, T.AL; Carvalho, C.R.L; Maia, N.B; Baggio, Study by Wagemaler, T.AL; Carvalho, C.R.L; Maia, N.B; Baggio,
S; Guerreiro Filho, O., intitulado "Sun protection factor and composition of lipid fraction of gree coffee beans" e publicado na revista Industrial Crops and Products, 33(2011 )469-473, mostrou que o principal agente envolvido na fotoproteção é o caveol, conforme descreve o Depósito de Pedido de Patente 221105532784 de 13/06/2011 do inventor Maia, N.B. Os autores da presente solicitação tentam encontrar novas aplicações ao óleo de café e a ação pró- cicatricial só pode ser observada quando utilizado o óleo obtido de grãos torrados de Coffea arábica. S; Guerreiro Filho, O., entitled "Sun protection factor and composition of lipid fraction of coffee beans" and published in the journal Industrial Crops and Products, 33 (2011) 469-473, showed that the main agent involved in photoprotection is caveol, as described in inventor Maia, NB Patent Application 221105532784 of 06/13/2011 The authors of this application try to find new applications for coffee oil and the pro-active action. can only be observed when using oil obtained from roasted Coffea arabica beans.
Como foi mencionado, não foi encontrado na literatura nenhum estudo in vivo sobre a ação do óleo de café, seja este verde (cru) ou torrado, relacionado com processos de cicatrização.  As mentioned, no in vivo studies on the action of coffee oil, whether green (roasted) or roasted, related to healing processes have been found in the literature.
Diante das informações disponíveis e, de certa forma, contrariando o estado da técnica, a presente invenção refere-se a uma composição a base de óleo de café, incluindo grãos de café torrado, para o tratamento de úlceras cutâneas. O uso tópico da referida composição influencia a produção sistémica - e não apenas no local de aplicação - de substâncias relacionadas à cicatrização, sugerindo que o uso da mesma apresenta uma ação cicatricial sistémica benéfica. Adicionalmente, a composição proposta apresenta vantagens sob vários aspectos. Primeiro, sobre as características de um produto eficaz para o tratamento de feridas devem incluir a facilidade de remoção do produto e o conforto do mesmo para o paciente, boa relação custo/benefício, manter a área cicatricial com umidade ideal e as áreas periféricas secas e protegidas, facilidade de aplicação e adaptabilidade (conformação às diversas partes do corpo). Outro diferencial do processo aqui descrito está relacionado com ação sistémica que a tecnologia possui, onde os níveis séricos de algumas substâncias foram alterados, assim como é capaz de acelerar o processo cicatricial em relação ao tipo de colágeno depositado no local, sendo mais eficaz que outros produtos comumente utilizados para este fim.  In the light of the available information and somewhat contrary to the state of the art, the present invention relates to a coffee oil based composition, including roasted coffee beans, for the treatment of skin ulcers. The topical use of this composition influences the systemic production - and not only at the site of application - of healing-related substances, suggesting that its use has a beneficial systemic healing action. Additionally, the proposed composition has advantages in several respects. First, the characteristics of an effective wound care product should include ease of removal and comfort for the patient, good value for money, keeping the healing area moist and dry and protected, ease of application and adaptability (conformation to different parts of the body). Another differential of the process described here is related to the systemic action that the technology has, where the serum levels of some substances have been altered, as well as being able to accelerate the healing process in relation to the type of collagen deposited in the site, being more effective than others. products commonly used for this purpose.
Breve Descrição da Invenção  Brief Description of the Invention
A presente invenção trata-se de uma composição a base de óleo de café de uso tópico com alta capacidade de cicatrização cutânea. Além disso, a presente invenção refere-se também ao uso e a formulação da referida composição.  The present invention is a coffee oil based topical composition with high skin healing ability. Furthermore, the present invention also relates to the use and formulation of said composition.
Breve descrição das figuras A estrutura e operação da presente invenção, juntamente com vantagens adicionais da mesma podem ser mais bem entendidas mediante referência às figuras em anexo e à seguinte descrição: Brief Description of the Figures The structure and operation of the present invention, together with further advantages thereof may be better understood by reference to the accompanying figures and the following description:
A Figura 1 mostra a área não cicatrizada dos ferimentos (%) ao longo de 10 dias de tratamento dos animais do Grupo 1 (Testemunha).  Figure 1 shows the unhealed area of wounds (%) over 10 days of treatment of Group 1 animals (Witness).
A Figura 2 mostra a área não cicatrizada dos ferimentos (%) ao longo de 10 dias de tratamento dos animais do Grupo 2 (AGE).  Figure 2 shows the unhealed wound area (%) over 10 days of treatment of Group 2 animals (AGE).
A Figura 3 mostra a área não cicatrizada dos ferimentos (%) ao longo de 10 dias de tratamento dos animais do Grupo 3 (Óleo de Café Cru),  Figure 3 shows the unhealed wound area (%) over 10 days of treatment of Group 3 animals (Crude Coffee Oil),
A Figura 4 mostra a área não cicatrizada dos ferimentos (%) ao longo de 10 dias de tratamento dos animais do Grupo 3 (Óleo de Café Torrado).  Figure 4 shows the unhealed wound area (%) over 10 days of treatment of Group 3 animals (Roasted Coffee Oil).
A Figura 5 apresenta um gráfico referente à celularidade no lado controle dos 4 grupos.  Figure 5 presents a graph regarding cellularity on the control side of the 4 groups.
A Figura 6 apresenta um gráfico referente à celularidade no lado tratado nos 4 grupos.  Figure 6 presents a graph regarding the cellularity on the treated side in the 4 groups.
Breve descrição do anexo Brief description of the attachment
O anexo 1 exemplifica o aspecto dos ferimentos no quarto dia de tratamento em uma das avaliações visuais realizadas.  Annex 1 exemplifies the appearance of injuries on the fourth day of treatment in one of the visual evaluations performed.
Descrição Detalhada da Invenção Detailed Description of the Invention
A presente invenção descreve uma composição tópica a base de óleo de café para cicatrização.  The present invention describes a topical healing coffee oil based composition.
Os principais exemplos de produtos que podem ser preparados partindo-se da composição, objeto da presente invenção, são:  The main examples of products which may be prepared from the composition object of the present invention are:
- Loção;  - lotion;
- Creme;  - cream;
- Pomada;  - ointment;
- Pós;  - Post;
- Sprays;  - sprays;
- Pastas;  - folders;
- Géis; - Suspensões e - gels; - Suspensions and
- Adesivos.  - Stickers.
A composição da presente invenção compreende os seguintes componentes:  The composition of the present invention comprises the following components:
- Óleo de café;  - coffee oil;
- Veículo farmaceuticamente aceitável.  - Pharmaceutically acceptable vehicle.
Além destes componentes, a composição da presente invenção ainda pode compreender componentes opcionais para proporcionar alguma característica desejável não alcançada com os componentes já citados, como emoliente, umectante, agente quelante, sistema espessante, componente antioxidante, sistema conservante, corantes e aromatizantes.  In addition to these components, the composition of the present invention may further comprise optional components to provide some desirable feature not achieved with the aforementioned components such as emollient, humectant, chelating agent, thickening system, antioxidant component, preservative system, colorants and flavorings.
Serão descritos a seguir com maiores detalhes os componentes utilizados na composição da presente invenção, bem como outros componentes opcionalmente adicionados na formulação. Para cada produto preparado as concentrações e componentes podem variar.  The components used in the composition of the present invention as well as other components optionally added in the formulation will be described in more detail below. For each product prepared the concentrations and components may vary.
Matéria-prima Feedstock
O café utilizado como matéria-prima para extração do óleo pode ser de qualquer tipo de classificação de mercado para bebida: mole, duro ou riados e de qualquer tipo de granulometria ou peneira utilizada para separação por tamanho de grãos.  Coffee used as an oil extraction raw material may be of any type of beverage market classification: soft, hard or rinded and of any type of grain size or sieve used for grain size separation.
A torra necessária para o processo é a mesma torra industrial utilizada para a produção de grãos destinados ao consumo como bebida, capaz de gerar as substâncias que promovem os aromas e sabor característico da bebida feita por infusão com água quente.  The roasting required for the process is the same industrial roasting used for the production of grain intended for consumption as a beverage, capable of generating the substances that promote the aroma and flavor characteristic of the beverage made by infusion with hot water.
O processo de extração do óleo pode ser tanto por compressão a frio como o utilizado no trabalho desenvolvido, como por extração com solventes simples ou em estado supercrítico. Porém, existem diferenças da quantidade de ácidos graxos essenciais encontrados em diferentes espécies de café. Isso foi observado no estudo "Sun protection factor and composition of lipid fraction of gree coffee beans", já mencionado, em que um dos autores da presente invenção (Maia, N.B.), foi um dos autores. Desta forma, os estudos realizados para a concretização da presente invenção permitem assegurar que o óleo de grãos torrados de Coffea arábica obtido por prensagem fria apresentou ação cicatrizante in vivo. Para a concretização da presente invenção, o café utilizado como matéria-príma foi adquirido diretamente do produtor e posteriormente encaminhado para torrefação e extração do óleo. Tal procedimento foi necessário pelo fato do sistema de comercialização e escala utilizada pelas torrefações serem muito maiores do que o volume de 12 sacas necessárias para obtenção dos óleos utilizados nos testes realizados. The oil extraction process can be either by cold compression as used in the work developed, or by extraction with simple or supercritical solvents. However, there are differences in the amount of essential fatty acids found in different coffee species. This was observed in the study "Sun protection factor and composition of lipid fraction of free coffee beans", mentioned above, in which one of the authors of the present invention (Maia, NB) was one of the authors. Thus, studies carried out for the embodiment of the present invention make it possible to ensure that the cold pressed oil of roasted Coffea arabica obtained healing action in vivo. For the embodiment of the present invention, the coffee used as raw material was purchased directly from the producer and later sent for roasting and oil extraction. This procedure was necessary because the commercialization system and scale used by the roasters are much larger than the 12 bags volume needed to obtain the oils used in the tests performed.
Além do uso de misturas para a formação de "blend", o café ofertado no mercado normal não tem o controle de lotes comprados pelas torrefações, não garantem a safra do produto (tempo de pós colheita), exige uma compra de no mínimo 20 sacas e não garantem ou especificam as condições de armazenamento. Para se ter um controle desses fatores se optou pela compra no produtor e posterior industrialização.  In addition to the use of blends to blend, the coffee offered in the normal market does not have control of lots purchased by roasters, do not guarantee the harvest of the product (post harvest time), requires a purchase of at least 20 bags. and do not guarantee or specify storage conditions. To have a control of these factors, it was decided to buy from the producer and later industrialization.
Como o volume mínimo para extração de óleo no equipamento utilizado era de seis sacas, foram adquiridas 12 sacas já beneficiadas, sendo 6 encaminhadas para um torrefação e utilizadas para obtenção de material para os tratamentos com óleo de café torrado e borra de filtro de café torrado. As demais foram direcionadas diretamente para a extração e produziram o óleo e a borra de filtro de café cru.  As the minimum volume for oil extraction in the equipment used was six bags, 12 bags were already benefited, being 6 sent to a roasting and used to obtain material for treatments with roasted coffee oil and roasted coffee filter sludge. . The others were directed directly to the extraction and produced crude coffee oil and filter dregs.
A torração do café foi feita em torrador comercial (Lilla®) com resfriamento a água e ventilação forçada para seis sacas para garantir um volume de matéria prima homogéneo, sem contaminações de outros lotes processados anteriormente ou posteriormente nos silos de passagem da indústria.  The roasting of the coffee was done in a commercial roaster (Lilla®) with water cooling and forced ventilation for six bags to ensure a homogeneous raw material volume, without contamination of other batches processed previously or later in the industry's silos.
O tratamento de torração utilizado foi o convencional aplicado para a produção de café para bebida interna, com um rendimento de 0,79 de café cru/torrado, que resultaram num total de 285kg de café torrado para extração de óleo de café torrado.  The roasting treatment used was the conventional one applied to the production of coffee for internal drink, with a yield of 0.79 of raw / roasted coffee, which resulted in a total of 285kg of roasted coffee for extraction of roasted coffee oil.
Extração e filtragem dos óleos O óleo de café empregado na presente invenção pode ser obtido por prensagem dos grãos.Tanto a extração por compressão a frio como o utilizado no trabalho desenvolvido, como por extração com solventes simples ou em estado supercrítico, são potencialmente capazes de produzir material adequado para o tratamento, desde que se obtenha tanto o óleo com a composição de ácidos graxos adequada, quanto as substâncias, por exemplo aquelas responsáveis pelo aroma e sabor característicos, geradas no processo de torra. O óleo adicionado a um veículo farmacologicamente aceitável em concentração variando entre 0,001% e 99,999%, preferencialmente 70% pode ser utilizado como cicatrizante Oil extraction and filtration The coffee oil employed in the present invention can be obtained by pressing the beans. Both cold compression extraction as used in the work developed, such as extraction with simple or supercritical solvents, are potentially capable of producing material suitable for treatment, provided that both the oil with the appropriate fatty acid composition and the substances, for example those responsible for the characteristic aroma and taste, generated in the roasting process are obtained. The oil added to a pharmacologically acceptable carrier at a concentration ranging from 0.001% to 99.999%, preferably 70% may be used as a healing agent.
A dosagem do óleo de café a ser usada depende de muitos fatores, tais como o agente causador, a idade, peso e condições clínicas do paciente assim como a experiência e julgamento do médico ou do profissional que administra a terapia. A quantidade efetiva do óleo de café é a que fornece melhora no paciente detectável por um profissional qualificado. O intervalo de dosagem varia com o composto usado, a via de administração e a potência do composto particular.  The dosage of coffee oil to be used depends on many factors such as the causative agent, the age, weight and clinical condition of the patient as well as the experience and judgment of the physician or practitioner administering the therapy. The effective amount of coffee oil is the one that provides patient improvement detectable by a qualified practitioner. The dosage range varies with the compound used, the route of administration and the potency of the particular compound.
Porém, para a concretização da presente invenção, os dois tipos de café (cru e torrado) foram encaminhados para extração em prensa industrial. O equipamento utilizado foi uma prensa (Piratininga®) do tipo "Expeller" adaptada para extração do óleo de grãos de café tanto cru como torrado. A máquina foi readaptada para receber moega, bandejas coletoras e vasos em aço inoxidável apropriados para obtenção de óleo para uso no experimento, sem contaminação de outras matérias primas ou óleos extraídos, garantindo ainda assim um produto de qualidade e possível de ser repetido em posterior industrialização.  However, for the embodiment of the present invention, both types of coffee (raw and roasted) were sent for extraction in industrial press. The equipment used was an "Expeller" (Piratininga®) press adapted for extracting oil from both raw and roasted coffee beans. The machine has been retrofitted to receive suitable stainless steel hoppers, collection trays and vessels to obtain oil for use in the experiment, without contamination of other raw materials or extracted oils, yet ensuring a quality product that can be repeated for later industrialization. .
As seis sacas de café para cada tipo de café cru e as seis de café torrado geraram respectivamente 23 e 38kg de óleo bruto. Esse volume foi compatível com o volume mínimo necessário de 20kg para operar o filtro do tipo prensa. O filtro prensa horizontal de fechamento manual foi especialmente construído para a filtragem sob alta pressão e obtenção de óleo límpido, além da separação da borra de filtro com alto teor de matéria não saponificável de interesse para ser utilizada nos tratamentos. A Tabela 1 apresenta os rendimentos do processo de extração realizados. The six coffee bags for each type of raw coffee and the six roasted coffee generated respectively 23 and 38kg of crude oil. This volume was compatible with the minimum required volume of 20kg to operate the press type filter. The hand-closing horizontal filter press is specially designed for high pressure filtration and clear oil production. the separation of filter sludge with high content of non-saponifiable material of interest for use in treatments. Table 1 shows the yields of the extraction process performed.
Tabela 1. Rendimentos do processo de extração de óleo de grãos de café (C. arábica) crú e torrado por prensa do tipo "expeller"  Table 1. Yields of the extraction process of coffee beans (C. arabica) crude and roasted by expeller press
Figure imgf000016_0001
Figure imgf000016_0001
Esterilização dos óleos  Sterilization of oils
O material processado na extração e filtragem foi acondicionado em frascos de vidro fechados, lacrados, com amostras identificadas que foram encaminhadas para teste de esterilização por raios gama para uma empresa que utiliza como emissor radioisótopo 60Co. Os diferentes materiais (óleo e borra de café cru e torrado) devidamente identificados foram submetidos às doses 3; 5; 7; 10; 12 e 15 KGy. The material processed in the extraction and filtering was packed in sealed glass bottles with identified samples that were sent for gamma sterilization testing to a company that uses 60 Co radioisotope emitter. The different materials (oil and coffee grounds) raw and roasted) properly identified were submitted to doses 3; 5; 7; 10; 12 and 15 KGy.
Após a irradiação foi realizado um estudo de contaminação em placas de cultura de microrganismos. Alíquotas de 20μΙ_ de material (óleo ou borra) obtido na filtragem na fábrica, para contagem de unidades formadoras de colónias em meios Ágar Sangue, Ágar Chocolate, BHI (Brain Heart Infusio) After irradiation, a contamination study was performed on microorganism culture plates. 20μΙ_ aliquots of material (oil or sludge) obtained from factory filtration to count colony forming units on Blood Agar, Chocolate Agar, BHI (Brain Heart Infusio) media
Caldo e Sabouraud, especial para fungos. Todas as amostras testadas inibiram o crescimento de microorganismos. Broth and Sabouraud, special for fungi. All samples tested inhibited the growth of microorganisms.
Por este motivo, optou-se por utilizar os óleos esterilizados com a menor dose de radiação (3KGy) para aplicação nos tratamentos dos ferimentos nos animais.  For this reason, we chose to use the sterilized oils with the lowest radiation dose (3KGy) for application in the treatment of animal injuries.
Análise dos óleos  Oil Analysis
Para caracterizar a proporção de ácidos graxos nos diferentes óleos extraídos e irradiados, uma alíquota do extrato lipídico contendo aproximadamente 400 mg de lipídios, foi seca em evaporador rotatório. A transmetilação foi realizada de acordo com o método de Hartman & Lago (1973), usando solução de cloreto de amónia e ácido sulfúrico em metanol como agente esterificante. To characterize the proportion of fatty acids in the different extracted and irradiated oils, an aliquot of the lipid extract containing approximately 400 mg of lipids was dried on a rotary evaporator. THE Transmethylation was performed according to the method of Hartman & Lago (1973), using ammonium chloride and sulfuric acid in methanol solution as esterifying agent.
A cromatografia gasosa foi realizada em um cromatógrafo a gás, marca Varian, modelo 3900, equipado com amostrador automático; injetor split, razão 75:1 ; coluna capilar CP-SIL 88 (100 m x 0,25 mm i.d., 0,20 μπι de filme); detector por ionização em chama (FID) e uma workstation para aquisição dos dados.  Gas chromatography was performed on a Varian model 3900 gas chromatograph equipped with an automatic sampler; split injector, ratio 75: 1; CP-SIL 88 capillary column (100 m x 0.25 mm i.d., 0.20 μπι film); flame ionization detector (FID) and a workstation for data acquisition.
Condições cromatográficas: temperatura da coluna programada, temperatura inicial 120°C/2min, aquecimento de 120°C a 220°C numa escala de 2,2°C/min e de 220 a 235°C numa escala de 1 ,5°C/min, permanecendo em Chromatographic conditions: programmed column temperature, initial temperature 120 ° C / 2min, heating from 120 ° C to 220 ° C on a scale of 2.2 ° C / min and from 220 to 235 ° C on a scale of 1.5 ° C / min remaining in
235°C por 15 minutos; gás de arraste, hidrogénio numa vazão de 1 mL/min; gás "make-up", nitrogénio a 30 mL/min; temperatura do injetor, 270°C; temperatura do detector, 310°C; volume de injeção 1 μL.235 ° C for 15 minutes; carrier gas, hydrogen at a flow rate of 1 mL / min; make-up gas, nitrogen at 30 mL / min; injector temperature, 270 ° C; detector temperature, 310 ° C; injection volume 1 μL.
5 A identificação dos ácidos graxos foi realizada através da comparação do tempo de retenção dos ácidos graxos das amostras e padrões e co-cromatografia. 5 Fatty acid identification was performed by comparing the retention time of the sample and standard fatty acids and co-chromatography.
A quantificação foi realizada por normalização de área e os resultados foram expressos em g/100g de amostra. Quantification was performed by area normalization and the results were expressed in g / 100g of sample.
0 Na Tabela 2 são apresentados os dados relativos à composição dos ácidos graxos dos óleos em função da torra dos grãos e dos tratamentos com raios gama. Não foi observada nenhuma diferença significativa em função da aplicação de nenhuma das doses de raios gama aplicadas. 0 Table 2 presents the data on the fatty acid composition of oils as a function of grain roasting and gamma ray treatments. No significant differences were observed as a function of the application of any of the gamma rays applied.
Tabela 2.: Composição (%) dos ácidos graxos dos óleos de café cru e torrado5 submetidos a diferentes doses de radiação gama para fins de esterilização.  Table 2: Composition (%) of fatty acids in raw and roasted coffee oils5 subjected to different doses of gamma radiation for sterilization purposes.
Café Torrado Café Crú  Roasted Coffee Raw Coffee
Dose Raios Gama Dose Raios Gama  Dose Range Rays Dose Range Rays
(K (K  (K (K
0 3 5 7 10 12 15 Mé 0 3 5 7 10 12 15 Mé 0 3 5 7 10 12 15 Mé 0 3 5 7 10 12 15 Mé
Ácido Acid
C14 0. 0. 0, 0. 0. 0, 0, 0.1 0. 0. 0. 0. 0, 0, 0, 0.1 C14 0. 0. 0, 0. 0. 0, 0, 0.1 0. 0. 0. 0. 0 0, 0, 0, 0.1
C16 31 31 31 31 31 31 31 31, 30 30 30 30 30 30 30 30,C16 31 31 31 31 31 31 31 31 31, 30 30 30 30 30 30 30 30,
C17 0, 0, 0, 0, 0, 0, 0, 0,1 0, 0, 0, 0, 0, 0, 0, 0C17 0, 0, 0, 0, 0, 0, 0.1, 0 0, 0, 0, 0, 0, 0, 0, 0
C18 8, 8, 8, 8, 8, 8, 8, 8.6 9, 9, 9, 9, 9, 9, 9, 9,3 C18:l 10 10 10 10 10 10 10 10, 9, 9, 9, 9, 9, 9, 9, 9,2C18 8, 8, 8, 8, 8, 8, 8, 8.6 9, 9, 9, 9, 9, 9, 9, 9.3 C18: 1 10 10 10 10 10 10 10 10 10, 9, 9, 9, 9, 9, 9, 9, 9.2
C18:2 38 38 38 38 38 37 38 38, 40 39 40 40 40 39 39 40,C18: 2 38 38 38 38 38 37 38 38, 40 39 40 40 40 39 39 40,
C18:3 1, 1, 1, 1, 1, 1, 1, 1,2 1, 1, 1, 1, 1, 1, 1, 1,1C18: 31 1, 1, 1, 1, 1, 1, 1,2, 1, 1, 1, 1, 1, 1, 1, 1.1
C20 3, 3, 3, 3, 3, 3, 3, 3,2 3, 3, 3, 3, 3, 3, 3, 3,3C20 3, 3, 3, 3, 3, 3, 3.2 3, 3, 3, 3, 3, 3, 3, 3.3
C21:l 0, 0, 0, 0, 1, 0, 0, 0,4 0, 0, 0, 0, 0, 0, 0, 0,2C21: 1.0, 0, 0, 0, 1, 0, 0, 0.4 0.4, 0, 0, 0, 0, 0, 0.2
C20:3 0, 0, 0, 0, 0, 0, 0, 0,2 0, 0, 0, 0, 0, 0, 0, 0,2C20: 3 0, 0, 0, 0, 0, 0, 0.2 0 0, 0, 0, 0, 0, 0, 0, 0.2
C22 0, 0, 0, 0, 0, 0, 0, 0,6 0, 0, 0, 0, 0, 0, 0, 0,8C22 0, 0, 0, 0, 0, 0, 0,6 0, 0, 0, 0, 0, 0, 0, 0,8
N.Knão 0, 0, 0, 0, 0, 0, 0,2 0, 0, 0, 0, 0, 0, 0,1N.Knot 0, 0, 0, 0, 0, 0, 0.2 0, 0, 0, 0, 0, 0, 0.1
C24 0, 0, 0, 0, 0, 0, 0, 0,2 0, 0, 0, 0, 0, 0, 0, 0,2 C24 0, 0, 0, 0, 0, 0, 0.2 0 0, 0, 0, 0, 0, 0, 0, 0.2
Ácidos Acids
Totaliza  Totals
Saturad 44 44 44 44 44 44 44 44. 44 44 44 44 44 44 44 44. onoin 11 11 11 11 11 10 11 11, 9, 9, 9, 9, 9, 9, 9, 9,4 Saturated 44 44 44 44 44 44 44 44. 44 44 44 44 44 44 44 44 44. onoin 11 11 11 11 11 10 11 11, 9, 9, 9, 9, 9, 9, 9, 9.4
Poliinsat 39 39 39 39 39 39 39 39, 41 41 41 41 41 41 41 41, ômega 6 38 38 38 38 38 38 38 38, 40 40 40 40 40 40 40 40, ômega 3 1, 1, 1, 1, 1, 1, 1, 1,2 1, 1, 1, 1, 1, 1, 1, 1,1 trans 0 0 0 0 0 0 0 0,0 0 0 0 0 0 0 0 0,0Polyinsat 39 39 39 39 39 39 39 39, 41 41 41 41 41 41 41 41 41, omega 6 38 38 38 38 38 38 38 38, 40 40 40 40 40 40 40 40, omega 3 1, 1, 1, 1, 1 , 1, 1, 1.2 1, 1, 1, 1, 1, 1, 1, 1.1 trans 0 0 0 0 0 0 0 0.0 0 0 0 0 0 0 0 0 0.0
N.l. (não 0, 0, 0, 0, 0, 0, 0 0,0 0, 0, 0, 0, 0, 0, 0 0,0 N.l. (not 0, 0, 0, 0, 0, 0, 0 0.0 0, 0, 0, 0, 0, 0, 0 0.0
Veículo farmaceuticamente aceitável: Pharmaceutically acceptable vehicle:
A absorção local e a eficácia da presente invenção pode ser melhorada utilizando-se como veículo uma quantidade apropriada de ácidos 5 graxos essenciais de cadeia média ou outros compostos químicos conhecidos por facilitar a absorção e entrega dos compostos ativos da presente invenção usada como veículo para o óleo de café. Este será o veículo preferencial da composição da presente invenção em um percentual adequado (q.s.p.) para atingir 100% da fórmula com base no peso total da composição. Ainda podem0 ser utilizados outros veículos farmaceuticamente aceitáveis como solução salina e tampões.  Local absorption and effectiveness of the present invention may be enhanced by using as appropriate carrier an appropriate amount of medium chain essential fatty acids or other chemical compounds known to facilitate absorption and delivery of the active compounds of the present invention used as a carrier for the preparation. coffee oil. This will be the preferred carrier of the composition of the present invention by a suitable percentage (q.s.p.) to achieve 100% of the formula based on the total weight of the composition. Still other pharmaceutically acceptable carriers may be used as saline and buffers.
Além destes componentes, a composição da presente invenção ainda pode compreender componentes opcionais tais como:  In addition to these components, the composition of the present invention may further comprise optional components such as:
- Agente quelante como ácido etilenodiaminotetraacético (EDTA) e5 seus sais;  - Chelating agent such as ethylenediaminetetraacetic acid (EDTA) and its salts;
- Agente ajustador de pH como trietanolamina ou hidróxidos inorgânicos;  PH adjusting agent such as triethanolamine or inorganic hydroxides;
- Agente conservante como parabenos, ácidos orgânicos, imidazolidininas, diazolidinas, álcoois fenólicos; - Emoliente como álcoois e ácidos graxos, ésteres, éteres, mono-, di- ou triglicerídeos, hidrocarbonetos naturais ou sintéticos ou carbonatos orgânicos e suas combinações. Preservative such as parabens, organic acids, imidazolidinines, diazolidines, phenolic alcohols; - Emollient such as alcohols and fatty acids, esters, ethers, mono-, di- or triglycerides, natural or synthetic hydrocarbons or organic carbonates and combinations thereof.
Umectante como glicóis, preferencialmente glicerina, propilenoglicol, butilenoglicol e suas combinações.  Humectant such as glycols, preferably glycerin, propylene glycol, butylene glycol and combinations thereof.
- Agente bacteriostático como hidroxibenzoato de metila, hidroxibenzoato de propilo, clorocresol, cloreto de benzalcônio e similares.  Bacteriostatic agent such as methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride and the like.
- Ingredientes ativos como antibióticos, anestésicos, analgésicos e descamativos. Exemplos de drogas representativas dentro dessas classes incluem gentamicina, peróxido de benzoíla, glicocorticoides, hidrocortisona, vitamina D3, metotrexate, ciclosporina, retinóides.  - Active ingredients such as antibiotics, anesthetics, pain killers and scaling. Examples of representative drugs within these classes include gentamicin, benzoyl peroxide, glucocorticoids, hydrocortisone, vitamin D3, methotrexate, cyclosporine, retinoids.
- Corantes;  - dyes;
- Aromatizantes.  - Flavoring.
A composição descrita no presente invento pode ser preparada empregando qualquer processo conhecido do estado da técnica. O óleo de café extraído através da prensagem dos grãos pode ser misturado sob condições estéreis com um veículo farmacologicamente aceito, e com qualquer conservante, tampão ou propelente que seja necessário. Preparados tópicos podem ser feitos combinando o óleo de café com diluentes farmacêuticos convencionais e veículos usados comumente em formulações tópicas secas, líquidas, em creme e aerossol. Pomadas e cremes podem, por exemplo, ser formulados com base aquosa ou lipídica com a adição de agentes espessantes ou geleificantes apropriados. As pomadas, cremes, pastas e géis podem conter também excipientes, tais como gorduras vegetais e animais, óleos, ceras, parafinas, amido, derivados de celulose, talco, óxido de zinco, silicones, polietilenoglicol, ácido silícico entre outros. Pós e sprays podem conter excipientes tais como lactose, talco, ácido silícico, hidróxido de alumínio, silicato de cálcio e pó de poliamida, ou uma mistura destas substâncias. Adicionalmente, os sprays podem conter propelentes, tais como clorofluorohidrocarbono, butano e propano.  The composition described in the present invention may be prepared employing any process known in the prior art. Coffee oil extracted by pressing the beans may be mixed under sterile conditions with a pharmacologically acceptable carrier, and with any preservative, buffer or propellant as required. Topical preparations can be made by combining coffee oil with conventional pharmaceutical diluents and commonly used carriers in dry, liquid, cream and aerosol topical formulations. Ointments and creams may, for example, be formulated with an aqueous or lipid base with the addition of suitable thickening or gelling agents. Ointments, creams, pastes and gels may also contain excipients such as vegetable and animal fats, oils, waxes, paraffins, starch, cellulose derivatives, talc, zinc oxide, silicones, polyethylene glycol, silicic acid among others. Powders and sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or a mixture of these substances. Additionally, sprays may contain propellants such as chlorofluorohydrocarbon, butane and propane.
Exemplo 1 : Testes in vivo Para os testes foram utilizadas fêmeas de ratos isogênicos da espécie Rattus norvegicus albinus linhagemNTacUnib:SD (SpragueDawIey), com idade média de 7 semanas e massa entre 220 a 270g. O experimento foi autorizado pela Comissão de Ética em Pesquisa Animal da Universidade Estadual de Campinas, de acordo com a Lei Federal 6.638. Example 1: In Vivo Testing For the tests we used isogenic rats of Rattus norvegicus albinus strain NTacUnib: SD (SpragueDawIey), with an average age of 7 weeks and weight between 220 to 270g. The experiment was approved by the Animal Research Ethics Committee of the State University of Campinas, according to Federal Law 6.638.
Após o período de adaptação nas gaiolas os animais foram preparados para a realização dos ferimentos e passaram a receber os tratamentos diários com os diferentes tipos de óleo, separados em "grupos" conforme indica a Tabela 3 abaixo. Em cada grupo de animais foram sub- divididos para serem sacrificados nos dias 2, 4 e 10 após a aplicação do primeiro tratamento.  After the cage adaptation period, the animals were prepared to perform the wounds and began to receive daily treatments with the different types of oil, separated into "groups" as shown in Table 3 below. In each group of animals they were subdivided to be sacrificed on days 2, 4 and 10 after the first treatment application.
A mudança dos períodos projetados para sacrifício de dois, sete e 14 dias, se deu porque observou-se clinicamente um processo de cicatrização mais rápido do que o previsto nos períodos menores de 4 e 10 dias as três fases da cicatrização poderiam ser avaliadas de modo mais adequado.  The change in the projected periods for two, seven and 14 day sacrifices occurred because a faster than expected healing process was clinically observed in the shorter periods of 4 and 10 days. most appropriate.
Respeítando-se o sentido da cabeça para a cauda, e/n todos os animais foram feitas quatro feridas do lado esquerdo, designadas como "A", "B", "C" e "D" e as do lado direito outras quatro designadas "E", "F", "G" e "H". O lado esquerdo recebeu sempre o produto de "Controle" ou "Testemunha" e o direito o "Tratamento".  Respecting the direction of the head to the tail, and / n all animals were made four wounds on the left side, designated "A", "B", "C" and "D" and those on the right side another four designated "E", "F", "G" and "H". The left side always received the product of "Control" or "Witness" and the right the "Treatment".
A Tabela 3 mostra esquematicamente a distribuição das feridas e dos tratamentos recebidos por cada grupo de animais.  Table 3 schematically shows the distribution of wounds and treatments received by each group of animals.
Tabela 3. Tratamentos aplicados em cada grupo de estudo.  Table 3. Treatments applied in each study group.
Lado Esquerdo (Controle) Lado Direito (Tratamento) Left Side (Control) Right Side (Treatment)
Grupo 1 Curativo oclusivo com gaze estéril Óleo mineral (Nujol®) Group 1 Sterile gauze occlusive dressing Mineral oil (Nujol®)
Ácidos Graxos Essenciais - Essential Fatty Acids -
Grupo 2 Óleo mineral (Nujol®) AGE® Group 2 Mineral Oil (Nujol®) AGE®
Grupo 3 Óleo mineral (Nujol®) Óleo de café cru Group 3 Mineral Oil (Nujol®) Raw Coffee Oil
Grupo 4 Óleo mineral (Nujol®) Óleo de café torrado Para receber o tratamento especificado e evitar estresse, cada animal foi conduzido para sala separada dos demais onde foi anestesiado com uma dose específica para sua classe de massa com quetamina 50mg.kg"1, xilazina 7,0 mg. kg'1 e diazepam 2,0 mg.kg"1 . Após estar completamente anestesiado as regiões paravertebrais e escapulares foram completamete tricotomizadas e foi feita desinfecção com uma solução de 2% de digliconato de clorexidina para assepsia da área onde seriam produzidas as feridas. Group 4 Mineral Oil (Nujol®) Roasted Coffee Oil To receive the specified treatment and avoid stress, each animal was taken to a separate room from the others where it was anesthetized with a specific dose for its ketamine mass class 50mg.kg "1 , xylazine 7.0 mg. kg '1 and diazepam 2.0 mg.kg "1. After being completely anesthetized the paravertebral and scapular regions were completely trichotomized and disinfected with a 2% chlorhexidine diglyconate solution for asepsis of the area where the wounds would be produced.
Na área tricotomizada foram feitas 4 feridas do lado direiro e outras 4 do lado esquerdo, cerda de 1 cm ao longo da coluna vertebral. Para uma melhor homogeniedade dos ferimentos tanto entre os 8 ferimentos de cada animal como entre todos os animais estudados, utilizou-se um bisturi circular descartável com 6mm de diâmetro para um corte na forma de disco em toda a profundidade da pele. O fragmento cutâneo em forma de disco era levantado por pinça e excisado com tesoura.  In the trichotomized area, 4 wounds were made on the right side and 4 on the left side, 1 cm bristle along the spine. For a better homogeneity of wounds between the 8 wounds of each animal and among all animals studied, a 6mm diameter disposable circular scalpel was used for a disc-shaped cut across the depth of the skin. The disc-shaped cutaneous fragment was lifted by forceps and excised with scissors.
Imediatamente após os ferimentos serem produzidos, o animal recebeu a primeira aplicação do produto específico para cada ferida como estipulado na Tabela 3, que foi coberta com uma gaze para cada lado do animal a fim de se evitar contaminação dos diferentes óleos aplicados no mesmo animal. A gaze foi presa por esparadrapo do tipo micropore e reforçada com esparadrapo externo. Diariamente os ferimentos foram limpos com soro fisiológico, os tratamentos repetidos com os respectivos óleos e os curativos substituídos até o dia determinado para o sacrifício. Para os curativos diários os animais não foram anestesiados para que não houvesse interferência no metabolismo hepático, uma vez que todos os animais aceitaram todos os procedimentos sem agressividade e foram tolerantes à manipulação. O dorso e cada ferimento de cada animal foram fotografados com câmara e lupa digital, respectivamente, para avaliação posterior.  Immediately after the injuries were produced, the animal received the first application of the wound-specific product as stipulated in Table 3, which was covered with gauze on each side of the animal to prevent contamination of the different oils applied to the same animal. The gauze was attached by micropore-type adhesive and reinforced with external adhesive. The wounds were cleaned daily with saline, the treatments repeated with the respective oils and the bandages replaced until the day determined for the sacrifice. For daily dressings, the animals were not anesthetized so that there was no interference with hepatic metabolism, since all animals accepted all procedures without aggression and were tolerant to manipulation. The back and each wound of each animal were photographed with camera and digital magnifying glass, respectively, for later evaluation.
Após sorteio para sacrifício nos dias 2, 4 ou 10 os animais em que haviam sido produzidos os ferimentos foram novamente anestesiados com tíopental (85,0 mg.kg"1), fotograficamente documentados e decaptados com guilhotina. Imediatamente após, o sangue foi coletado para as dosagens das substâncias relacionadas com inflamação pela técnica Elisa. After a draw for sacrifice on days 2, 4 or 10, the animals in which the injuries were produced were again anesthetized with thiopental (85.0 mg.kg "1 ), photographically documented and decapitated with guillotine. Immediately after, blood was collected. for dosing of inflammation-related substances by the Elisa technique.
A pele das áreas tricotomizadas da região dorsal foram excisadas até a fáscia, separando-se as metades proximais, com duas feridas de cada lado para fixação em formal a 10% até o preparo das lâminas para avaliação histopatológica. The skin of the trichotomized areas of the dorsal region was excised to the fascia, separating the proximal halves, with two wounds on each side. side for 10% formal fixation until slide preparation for histopathological evaluation.
Novas biópsias com lâminas circulares de mesmo diâmetro foram feitas nos quatro pontos das biópsias anteriores na porção caudal da pele excisada. Cada um dos quatro fragmentos de derme ou pele retirados foram imediatamente identificados e colocados em recipiente contendo nitrogénio líquido sendo crioconservados a -80°C no final do período do experimento até o preparo para as dosagens teciduais (PCR real time) das substâncias associadas à apoptose.  New biopsies with circular slides of the same diameter were made at the four points of the anterior biopsies in the caudal portion of the excised skin. Each of the four dermis or skin fragments removed were immediately identified and placed in a container containing liquid nitrogen and cryopreserved at -80 ° C at the end of the experiment until preparation for the real time PCR of apoptosis-associated substances. .
A avaliação visual feita durante a manipulação diária de cada um dos animais, para renovação do tratamento, registro fotográfico e troca de curativos, indicou uma melhora significativa dos animais do Grupo 4 tratados com óleo de café torrado. A partir do segundo ou terceiro dia pod/a-se observar uma cicatrização mais efetiva dos ferimentos. No Anexo 1 pode-se observar um exemplo do aspecto dos ferimentos no quarto dia de tratamento.  Visual assessment during daily manipulation of each animal for treatment renewal, photographic recording and dressing change indicated a significant improvement in the Group 4 animals treated with roasted coffee oil. From the second or third day, a more effective wound healing can be observed. An example of the appearance of injuries on the fourth day of treatment can be seen in Annex 1.
No dia de sacrifício de cada animal, os ferimentos animais foram fotografados com distância focal constante, de modo a manter a mesma escala em todas as imagens. As áreas não cicatrizadas foram quantificadas em número de "pixel". As escalas das fotografias das peças excisadas foram corrigidas para determinação da área, utilizando-se o programa " ImageTool v.3 UTHSCSA - The University of Texas Health Science Center in San Antonio". Nos Anexos 2, 3, 4, e 5 estão as fotos de todas as peças. Nas Tabelas 4, 5 e 6 são apresentados as áreas obtidas e as análises parciais das regressões dos ferimentos.  On the sacrificial day of each animal, the animal wounds were photographed at constant focal length to maintain the same scale on all images. Unhealed areas were quantified in pixel number. Photo scales of excised specimens were corrected for area determination using the "ImageTool v.3 UTHSCSA - The University of Texas Health Science Center in San Antonio" program. In Attachments 2, 3, 4, and 5 are photos of all parts. Tables 4, 5 and 6 show the areas obtained and partial analysis of the regressions of the injuries.
Tabela 4. Áreas em pixel dos ferimentos tratados por 2 dias.  Table 4. Pixel areas of wounds treated for 2 days.
D2 02 02 D2 D2 D2 D2 D2  D2 02 02 D2 D2 D2 D2 D2
G1 2240 G2 2758 G3 2720 G4 1153  G1 2240 G2 2758 G3 2720 G4 1153
G1 3635 G2 4928 G3 2161 G4 957  G1 3635 G2 4928 G3 2161 G4 957
G1 1556 G2 4044 G3 5815 G4 577  G1 1556 G2 4044 G3 5815 G4 577
G1 2355 G2 4180 G3 6424 G4 1391  G1 2355 G2 4180 G3 6424 G4 1391
G1 4758 G2 3601 G3 0 G4 0  G1 4758 G2 3601 G3 0 G4 0
G1 4059 G2 7246 G3 3039 G4 269  G1 4059 G2 7246 G3 3039 G4 269
G1 6115 G2 7893 G3 2177 G4 2058 G1 3886 G2 3996 G3 0 G4 2881G1 6115 G2 7893 G3 2177 G4 2058 G1 3886 G2 3996 G3 0 G4 2881
G1 3522 G2 5101 G3 4434 G4 198G1 3522 G2 5101 G3 4434 G4 198
G1 6922 G2 3976 G3 2536 G4 1490G1 6922 G2 3976 G3 2536 G4 1490
G1 5448 G2 4577 G3 3692 G4 2490G1 5448 G2 4577 G3 3692 G4 2490
G1 4907 G2 4172 G3 4676 G4 3214G1 4907 G2 4172 G3 4676 G4 3214
G1 3251 G2 4128 G3 3343 G4 3278G1 3251 G2 4128 G3 3343 G4 3278
G1 4152 G2 3270 G3 2774 G4 1355G1 4152 G2 3270 G3 2774 G4 1355
G1 4236 G2 3343 G3 4665 G4 1360G1 4236 G2 3343 G3 4665 G4 1360
G1 6495 G2 5676 G3 3355 G4 1607G1 6495 G2 5676 G3 3355 G4 1607
G1 1713 G2 235 G3 4906 G4 313G1 1713 G2 235 G3 4906 G4 313
G1 2416 G2 3573 G3 4391 G4 2311G1 2416 G2 3573 G3 4391 G4 2311
G1 3661 G2 2953 G3 5809 G4 2060G1 3661 G2 2953 G3 5809 G4 2060
G1 1544 G2 4127 G3 6417 G4 3609 G1 1544 G2 4127 G3 6417 G4 3609
Tabela 5. Áreas em pixel dos ferimentos tratados or 4 dias.Table 5. Pixel areas of wounds treated or 4 days.
D4 D4 D4 D4 D4 D4 D4 D4D4 D4 D4 D4 D4 D4 D4 D4
G1 7248 G2 12988 G3 4939 G4 791G1 7248 G2 12988 G3 4939 G4 791
G1 1068 G2 7809 G3 2974 G4 4381G1 1068 G2 7809 G3 2974 G4 4381
G1 4842 G2 7099 G3 3016 G4 2307G1 4842 G2 7099 G3 3016 G4 2307
G1 3085 G2 5894 G3 3513 G4 2419G1 3085 G2 5894 G3 3513 G4 2419
G1 17033 G2 6980 G3 3140 G4 2076G1 17033 G2 6980 G3 3140 G4 2076
G1 3394 G2 1578 G3 3033 G4 3512G1 3394 G2 1578 G3 3033 G4 3512
G1 5882 G2 12355 G3 2985 G4 6348G1 5882 G2 12355 G3 2985 G4 6348
G1 5573 G2 8151 G3 2203 G4 6460G1 5573 G2 8151 G3 2203 G4 6460
G1 16062 G2 3060 G3 3014 G4 0G1 16062 G2 3060 G3 3014 G4 0
G1 3818 G2 1301 G3 2333 G4 5585G1 3818 G2 1301 G3 2333 G4 5585
G1 4162 G2 10792 G3 3882 G4 6676G1 4162 G2 10792 G3 3882 G4 6676
G1 5349 G2 3874 G3 3807 G4 7480G1 5349 G2 3874 G3 3807 G4 7480
G1 4986 G2 2593 G3 2935 G4 5136G1 4986 G2 2593 G3 2935 G4 5136
G1 3533 G2 5331 G3 2973 G4 5547G1 3533 G2 5331 G3 2973 G4 5547
G1 4013 G2 7097 G3 3022 G4 5564G1 4013 G2 7097 G3 3022 G4 5564
G1 4013 G2 5227 G3 3724 G4 4654G1 4013 G2 5227 G3 3724 G4 4654
G1 G2 11235 G3 3088 G4 4756G1 G2 11235 G3 3088 G4 4756
G1 G2 6222 G3 2902 G4 2886G1 G2 6222 G3 2902 G4 2886
G1 G2 5015 G3 3578 G4 3418G1 G2 5015 G3 3578 G4 3418
G1 G2 11205 G3 3944 G4 5779 G1 G2 11205 G3 3944 G4 5779
Tabela 6. Áreas em pixel dos ferimentos tratados por 10 dias.Table 6. Pixel areas of wounds treated for 10 days.
D10 D10 D10 D10 D10 D10 D10 D10D10 D10 D10 D10 D10 D10 D10 D10
G1 40 G2 0 G3 0 G4 55G1 40 G2 0 G3 0 G4 55
G1 116 G2 134 G3 0 G4 0 G1 127 G2 0 G3 0 G4 0 G1 116 G2 134 G3 0 G4 0 G1 127 G2 0 G3 0 G4 0
G1 185 G2 0 G3 71 G4 0  G1 185 G2 0 G3 71 G4 0
G1 0 G2 0 G3 0 G4 0  G1 0 G2 0 G3 0 G4 0
G1 7 G2 0 G3 582 G4 0  G1 7 G2 0 G3 582 G4 0
G1 0 G2 840 G3 1688 G4 0  G1 0 G2 840 G3 1688 G4 0
G1 24 G2 846 G3 5056 G4 0  G1 24 G2 846 G3 5056 G4 0
G1 39 G2 0 G3 0 G4 0  G1 39 G2 0 G3 0 G4 0
G1 196 G2 0 G3 0 G4 2214  G1 196 G2 0 G3 0 G4 2214
G1 211 G2 226 G3 0 G4 0  G1 211 G2 226 G3 0 G4 0
G1 418 G2 142 G3 291 G4 238  G1 418 G2 142 G3 291 G4 238
G1 0 G2 0 G3 24 G4 0  G1 0 G2 0 G3 24 G4 0
G1 85 G2 1147 G3 3295 G4 0  G1 85 G2 1147 G3 3295 G4 0
G1 58 G2 255 G3 4231 G4 0  G1 58 G2 255 G3 4231 G4 0
G1 62 G2 361 G3 19 G4 0  G1 62 G2 361 G3 19 G4 0
G1 74 G2 198 G3 0 G4 0  G1 74 G2 198 G3 0 G4 0
G1 87 G2 0 G3 0 G4 0  G1 87 G2 0 G3 0 G4 0
G1 16 G2 120 G3 340 G4 0  G1 16 G2 120 G3 340 G4 0
G1 18 G2 154 G3 677 G4 216  G1 18 G2 154 G3 677 G4 216
Determinou-se para cada ferimento tratado, do lado direito do animal, a redução relativa ao seu oposto topográfico, do lado esquerdo, não tratado. Desse modo pode-se quantificar proporcionalmente quanto do ferimento tratado permaneceu sem cicatrização após o início do experimento, em relação aos ferimentos, do mesmo animal e no mesmo plano transversal. Considerou-se que no dia zero 100%. For each treated wound on the right side of the animal, the reduction relative to its topographic opposite on the left untreated side was determined. Thus, it can be proportionally quantified how much of the treated wound remained unhealed after the beginning of the experiment, in relation to the injuries of the same animal and in the same transverse plane. It was considered that on day zero 100%.
Nas Figuras 1 , 2, 3 e 4, respectivamente são apresentadas as curvas da regressão Polinomial de segundo grau, da porcentagem da área ferida não cicatrizada nos animais dos Grupol (testemunha), Grupo 2 (AGE), Grupo 3 (Óleo de Café Crú) e Grupo 4 (Óleo de Café Torrado). No eixo X são indicados os números de dias de tratamento e o no eixo Y o percentual da área ferida, não cicatrizada, considerando-se que no dia Zero todos os ferimentos estavam com a mesma área (100%)  Figures 1, 2, 3 and 4, respectively, show the curves of the second degree polynomial regression, of the percentage of unhealed wound area in the Group (control), Group 2 (AGE), Group 3 (Raw Coffee Oil) animals. ) and Group 4 (Roasted Coffee Oil). X-axis shows the number of days of treatment and Y-axis the percentage of the unhealed area, considering that on day zero all injuries were in the same area (100%).
As barras verticais vermelhas representam quando a curva de cicatrização média atingiu 75% de ferimento e 25% cicatrizada e as barras negras quando 50% da área estava cicatrizada. Na Figura 1 , observa-se que os 25% e 50% de cicatrização foram atingidos aos 4,7 e 7,7dias após o início do tratamento. The red vertical bars represent when the average healing curve reached 75% wound and 25% healed and the black bars represent when 50% of the area was healed. Figure 1 shows that 25% and 50% healing was achieved at 4.7 and 7.7 days after the start of treatment.
Os resultados do cálculo das derivadas das equações polinomiais das regressões são apresentados na Tabela 7. O parâmetro (a) das equações de primeiro grau representa o ponto de máxima das regressões de segundo grau e indica o tempo necessário em dias para que a curva atinja o valor zero, ou seja, a cicatrização total do ferimento. Assim quanto mais distante do zero, menor é o efeito inicial de cicatrização do tratamento. Assim, observa-se que o tratamento com AGE teve um efeito inicial melhor do que todos os outros.  The results of calculating the derivatives of the polynomial regression equations are presented in Table 7. Parameter (a) of the first degree equations represents the maximum point of the second degree regressions and indicates the time required in days for the curve to reach zero value, ie the total wound healing. So the farther from zero, the lower the initial healing effect of the treatment. Thus, AGE treatment was found to have a better initial effect than all others.
O parâmetro (b) indica a inclinação da reta, no caso com valores negativos, é a representação gráfica da área sem cicatrização. Quanto mais inclinada, maior a velocidade de cicatrização. A inclinação das curvas representa os efeitos acumulados ao longo do tempo, corroborando com as observações clínicas, de que os animais tratados com óleo de café torrado apresentaram uma significativa melhora após o quarto dia de tratamento.  Parameter (b) indicates the slope of the line, in the case with negative values, is the graphical representation of the area without healing. The more inclined, the faster the healing rate. The slope of the curves represents the accumulated effects over time, corroborating with clinical observations that animals treated with roasted coffee oil showed a significant improvement after the fourth day of treatment.
Tabela 7. Derivadas das equações de regressão polinomial de segundo grau (y'=a+bx) dos quatro tratamentos estudados.  Table 7. Derivatives of the second degree polynomial regression equations (y '= a + bx) of the four treatments studied.
Figure imgf000025_0001
Figure imgf000025_0001
Na Tabela 8 são resumidos os dias necessários para se atingir 25% e 50% de cicatrização do ferimento inicial e a derivada de segundo grau das curvas. Como os números analisados correspondem ao percentual da área sem cicatrização, o valor negativo da derivada de segundo grau da função polinomial representa a aceleração da cicatrização (% de cicatrização dividido pelo quadrado do tempo) de cada tratamento. Tabela 8. Número de dias para cicatrização de 25% e 50% das áreas tratadas e valor da derivada de segundo grau. Table 8 summarizes the days required to achieve 25% and 50% initial wound healing and the second degree derivative of the curves. Since the numbers analyzed correspond to the percentage of the area without healing, the negative value of the second degree derivative of polynomial function represents the healing acceleration (% of healing divided by the time square) of each treatment. Table 8. Number of days for healing of 25% and 50% of the treated areas and value of the second degree derivative.
Figure imgf000026_0001
Figure imgf000026_0001
δ ": aceleração de cicatrização  δ ": healing acceleration
Os animais responderam aos tratamentos com diferentes acelerações de cicatrização. Em ordem crescente o tratamento Testemunha, seguido do Óleo de Café Cru, AGE e Óleo de Café Torrado.  The animals responded to the treatments with different healing accelerations. In increasing order the Witness treatment, followed by Raw Coffee Oil, AGE and Roasted Coffee Oil.
Houve evidente diferença clínica na cicatrização do lado em que só foi realizada a limpeza com soro fisiológico e o lado tratado com óleo mineral nos animais do grupo 1. Esta observação reforça o conhecimento descrito desde 1945 de que a cicatrização é mais efetiva mantendo-se o ambiente úmido (Field & Kerstein, 1994). Os animais do grupo dois (AGE) e do grupo três (óleo de café cru) apresentaram processo cicatricial comparável clinicamente. Os ratos tratados com óleo de café torrado apresentaram a melhor recuperação ao longo do período de 10 dias tratamento, tendo sido possível observar melhora já a partir do terceiro dia.  There was a clear clinical difference in healing on the side that was only cleaned with saline and the side treated with mineral oil in the animals of group 1. This observation reinforces the knowledge described since 1945 that healing is more effective maintaining humid environment (Field & Kerstein, 1994). The animals from group two (AGE) and group three (crude coffee oil) presented clinically comparable healing process. The rats treated with roasted coffee oil showed the best recovery over the 10 days treatment period, and it was possible to observe improvement from the third day.
Os resultados encontrados com a medida das áreas das úlceras mostraram maior velocidade de cicatrização de forma crescente com o AGE, óleo de café cru e óleo de café torrado. A área cicatricial, contudo, por vezes era difícil de ser medida pela presença de crostas que não se destacavam com a limpeza realizada de forma delicada. As crostas que persistiam não eram removidas porque a avaliação objetiva histológica foi o parâmetro considerado mais relevante.  The results found with the measurement of ulcer areas showed a faster healing rate with increasing AGE, crude coffee oil and roasted coffee oil. The healing area, however, was sometimes difficult to measure by the presence of scabs that did not detach from gentle cleaning. Persistent crusts were not removed because objective histological evaluation was the most relevant parameter.
Exemplo 2: Análise histológica  Example 2: Histological Analysis
O preparo das lâminas para a análise histológica foi realizado da seguinte forma: os ferimentos da porção proximal foram conservados inicialmente em álcool e posteriormente em formol em frascos individuais devidamente identificados para a elaboração das lâminas para a análise histológica. Após a extração de cada ferida de uma seção longitudinal abrangendo todo o ferimento ou cicatriz remanescente, a peça foi corada pelo método de Hematoxilina e Eosina (HE) e contida em bloco de parafina para o trabalho em micrótomo e montagem da referida lâmina. The preparation of slides for histological analysis was performed as follows: the proximal portion injuries were preserved initially in alcohol and later in formaldehyde in individual bottles properly identified for the preparation of slides for histological analysis. After extraction of each wound from a longitudinal section covering the entire remaining wound or scar, the piece was stained by the Hematoxylin and Eosin (HE) method and contained in paraffin block for microtome work and assembly of the referred blade.
As lâminas foram analisadas subjetivamente e objetivamente para estimativa da taxa de cicatrização dos ferimentos de forma cega, isto é, sem que os avaliadores soubessem a identificação da lâmina que examinavam. 1 ) Avaliação histológica subjetiva  The blades were subjectively and objectively analyzed to estimate the wound healing rate blindly, that is, without the evaluators knowing the identification of the blade they were examining. 1) Subjective histological evaluation
A avaliação histológica subjetiva foi feita de maneira cega, isto é, a médica dermatopatologista que participou do projeto, fez a avaliação sem saber a identificação das lâminas que examinava.  Subjective histological evaluation was done blindly, that is, the dermatopathologist who participated in the project made the evaluation without knowing the identification of the slides she was examining.
No dia 2 (fase inflamatória) pode-se observar que a reepitelização já havia iniciado, ou seja, a epiderme começava a proliferar para cobrir a ferida (quanto mais acelerada a cicatrização, maior a extensão da ferida que já apresentava reepitelização), porém, nesta fase do processo, não se justificava avaliar a extensão da ferida que já se encontrava reepitelizada, porque todos os animais estavam começando este processo. Os vasos estavam muito congestos; quanto maior o número de vasos dilatados, nesta fase, melhor para que a cicatrização ocorra. Foi feita uma avaliação subjetiva: 0= leve; 1 = evidente. Na fase seguinte, eles já não estavam tão dilatados, mas as suas células começaram a proliferar e foram avaliadas no item "celularidade".  On day 2 (inflammatory phase) it can be observed that the reepithelialization had already started, that is, the epidermis began to proliferate to cover the wound (the faster the healing, the greater the extent of the wound that already had reepithelization), however, At this stage of the procedure, it was not justified to assess the extent of the wound that was already reepithelized, because all animals were beginning this process. The vessels were very congested; The greater the number of dilated vessels at this stage, the better for healing to occur. A subjective assessment was made: 0 = mild; 1 = evident. In the next phase, they were no longer as dilated, but their cells began to proliferate and were evaluated in the item "cellularity".
O tecido colágeno dérmico bem imaturo começou a ser observado, pouco celular, com muita substância fundamental basófila. Sabe-se que para esta fase, quanto mais tecido conjuntivo jovem, mais adiantada está a cicatrização. As células deste tecido conjuntivo já podem começar a aparecer nesta fase da cicatrização e quanto mais presentes, melhor o processo cicatricial. A celularidade também foi estimada, de forma subjetiva: 0= muito baixa; 1 = baixa; 2= evidente; a porcentagem de colágeno jovem presente na cavidade operatória também foi estimada de forma subjetiva. Apesar de não haver avaliação histológica no dia 3, pode-se inferir avaliando os animais do dia 4 que nesta fase houve um significante aumento da celularidade. Estas eram células endoteliais (de vasos neoformados, que trazem nutrição para ajudar a cicatrizar) e células produtoras de colágeno (fibroblastos e miofibroblastos). O colágeno pode ser observado em maior quantidade no dia 4 naqueles com cicatrização mais adiantada. The very immature dermal collagen tissue began to be observed, little cellular, with much basophil fundamental substance. It is known that for this phase, the more young connective tissue, the earlier the healing. The cells of this connective tissue may already begin to appear at this stage of healing and the more present, the better the healing process. Cellularity was also estimated, subjectively: 0 = very low; 1 = low; 2 = evident; The percentage of young collagen present in the operative cavity was also subjectively estimated. Although there is no histological evaluation on day 3, it can be inferred by evaluating the animals on day 4 that in this phase there was a significant increase in cellularity. These were endothelial cells (from newly formed vessels that bring nutrition to help heal) and collagen-producing cells (fibroblasts and myofibroblasts). Collagen may be seen in greater quantity on day 4 in those with earlier healing.
No dia 4 a fase proliferativa, reepitelização, já estava bem avançada, com maior extensão da área de reepitelização. A cicatrização foi avaliada: (0= incipiente; 1 = avançada; 2= completa ou quase completa).  By day 4 the proliferative phase, reepithelialization, was already well advanced, with a larger extension of the reepithelialization area. Healing was evaluated: (0 = incipient; 1 = advanced; 2 = complete or almost complete).
Nesta fase ainda havia um significante número de células, mas, nos animais em fase mais adiantada de cicatrização, a celularidade que se iniciou no 39 dia começa a diminuir já que, à medida que o colágeno vai sendo produzido, ele vai inibindo a produção de células (chamada inibição de contato) e, nos animais nestes animais com cicatrização mais adiantada já havia colágeno maduro. Naqueles com cicatrização menos efetiva havia mais células e menos colágeno maduro (observado como fibras acidófilas mais espessas) e bastante colágeno imaturo, como no 2- dia. A cavidade formada no experimento em parte já se encontrava preenchida; contudo, não a área central. Foi estimada de forma subjetiva a porcentagem de preenchimento relativa à pele normal adjacente (em 5). Quanto ao tecido que preenchia a ferida e que continha células, fibrina, colágeno jovem e colágeno maduro; a quantidade de fibras colágenas maduras foi estimada, de forma subjetiva (0= nenhuma quantidade; 1 = poucas fibras; 2= fibras mais evidente; 3= várias fibras; 4= numerosas fibras). At this stage there were still a significant number of cells, but in the animals in the early stage of healing, the cellularity that began on day 39 begins to decrease as, as collagen is produced, it inhibits production. cells (called contact inhibition) and in the animals in these animals with earlier healing there was already mature collagen. Those with less effective healing had more cells and less mature collagen (observed as thicker acidophilic fibers) and quite immature collagen, as on day 2. The cavity formed in the experiment was already partially filled; however, not the central area. It was subjectively estimated the percentage of filling relative to the adjacent normal skin (in 5). As for the tissue that filled the wound and contained cells, fibrin, young collagen and mature collagen; The amount of mature collagen fibers was subjectively estimated (0 = no amount; 1 = few fibers; 2 = more evident fibers; 3 = several fibers; 4 = numerous fibers).
No dia 10 (fase de remodelação) os animais já tinham a reepitelização completa. Alguns ainda tinham resquícios do colágeno jovem (o mesmo do 2- dia) que ainda não foi substituído pelo maduro, de fibras espessas. Uma boa parte da cavidade formada no experimento já se encontra preenchida; contudo, a área central ainda estava deprimida, relativamente à pele normal adjacente. O preenchimento foi estimado em porcentagem. Com relação ao tecido que estava preenchendo a ferida operatória, nesta fase observaram-se áreas mais celulares e outras menos, em proporção inversa à do número de fibras colágenas maduras. Foi feita uma estimativa percentual da quantidade de fibras colágenas maduras que ocupavam o tecido que estava preenchendo a ferida. At day 10 (remodeling phase) the animals already had complete reepithelization. Some still had remnants of the young collagen (the same as day 2) which has not yet been replaced by the mature, thick fiber. Much of the cavity formed in the experiment is already filled; however, the central area was still depressed relative to adjacent normal skin. Fill was estimated as a percentage. Regarding the tissue that was filling the surgical wound, in this phase more and less cellular areas were observed, in inverse proportion to the number of mature collagen fibers. A percentage estimate of the amount of mature collagen fibers that occupied the tissue filling the wound was made.
A avaliação subjetiva não evidenciou diferença estatística entre os grupos, porém, no segundo dia do experimento, observou-se uma melhor cicatrização nos animais que utilizaram o óleo de café cru e o óleo de café torrado nos parâmetros observados no segundo dia. No quarto dia, os achados sugeriram menor celularidade nos três grupos: AGE, óleo de café cru e óleo de café torrado, contudo o preenchimento aparentou ser maior nos animais do grupo sem tratamento. No dia 10 do experimento o preenchimento foi melhor com o óleo de café torrado.  Subjective evaluation showed no statistical difference between the groups, however, on the second day of the experiment, better healing was observed in the animals that used crude coffee oil and roasted coffee oil in the parameters observed on the second day. On the fourth day, the findings suggested lower cellularity in the three groups: AGE, crude coffee oil and roasted coffee oil, however the filling appeared to be higher in the animals of the untreated group. On day 10 of the experiment the filling was better with roasted coffee oil.
2) Avaliação histológica objetiva 2) Objective histological evaluation
A avaliação objetiva foi realizada em microscópio com tela de ciclóide para contagem de células. Foi avaliado o número de células nos cortes, responsáveis pela cicatrização dos ferimentos. Para tanto quantificaram-se os núcleos celulares que tocavam os semi-círculos do ciclóide.  Objective evaluation was performed under a microscope with a cycloid screen for cell counting. The number of cells in the cuts responsible for wound healing was evaluated. For this, the cell nuclei that touched the cycloid half circles were quantified.
No ciclóide há 30 semi-círculos. Cada núcleo que tocou um dos ciclóides ou semi-círculos foi contado. Este é um método comparativo, que mostra se a cicatrização está desenvolvida (adulta, composta de fibrócitos) ou se ainda é jovem (composta por fibroblastos). Na "fase adulta", o número de núcleos é pequeno; na "fase jovem", o número de núcleos é maior. Dessa forma, se uma amostra tem muitos núcleos, pode-se dizer que o tecido é jovem (ainda está no início do processo cicatricial).  In the cycloid there are 30 half circles. Each nucleus that touched one of the cycloids or half circles was counted. This is a comparative method that shows whether healing is developed (adult, composed of fibrocytes) or if it is still young (composed of fibroblasts). In the "adult phase" the number of nuclei is small; In the "young phase", the number of nuclei is higher. Thus, if a sample has many nuclei, it can be said that the tissue is young (it is still at the beginning of the healing process).
A análise objetiva foi baseada na contagem da celularidade, como já descrita anteriormente e é o parâmetro mais importante na análise do efeito dos tratamentos sobre a cicatrização.  Objective analysis was based on cellularity count, as previously described, and is the most important parameter in the analysis of the effect of treatments on healing.
A menor celularidade foi observada nas úlceras tratadas com o The lowest cellularity was observed in ulcers treated with
AGE e com o óleo de café torrado quando comparadas com o lado coníralateral em que as úlceras foram tratadas com óleo mineral o que documentou uma melhor cicatrização com estes óleos. As úlceras tratadas com o óleo de café cru tiveram cicatrização pior que quando foi usado apenas óleo mineral e soro fisiológico nas úlceras dos animais do grupo 1 . AGE and roasted coffee oil when compared to the side in which the ulcers were treated with mineral oil which documented better healing with these oils. Ulcers treated with crude coffee oil had worse healing than when only mineral oil and saline were used in the ulcers of group 1 animals.
Exemplo 3: PCR quantitativo (qPCR) - PCR real time (análise de citocinas inflamatórias no tecido cicatricial) Example 3: Quantitative PCR (qPCR) - Real time PCR (analysis of inflammatory cytokines in scar tissue)
Foi feita a avaliação tecidual com Real-Time PCR para procurar entender a ação local do produto utilizado e avaliação sorológica para avaliar possível ação sistémica do produto utilizado sobre a derme.  Real-Time PCR tissue evaluation was performed to understand the local action of the product used and serological evaluation to evaluate possible systemic action of the product used on the dermis.
As citocinas inflamatórias avaliadas têm diferentes ações sobre o processo cicatricial e umas têm ação mais intensa nas fases iniciais da cicatrização. Por esta razão as dosagens, além da avaliação histológica, também foram feitas nas diferentes fases da cicatrização: D2, fase inflamatória; D4, fase proliferativa e D10, início da fase de remodelação que se extende por meses.  The evaluated inflammatory cytokines have different actions on the healing process and some have more intense action in the early stages of healing. For this reason the dosages, besides the histological evaluation, were also made in the different healing phases: D2, inflammatory phase; D4, proliferative phase and D10, beginning of remodeling phase that extends for months.
Foi feita extração de RNA total das amostras de pele congeladas à -809C, segundo método do reagente Qiazol (Qiagen, USA). Para a produção do cDNA, utilizamos o kit High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), sendo a concentração final do cDNA de 3,0 [ lg. Este cDNA foi diluído segundo a concentração necessária para a amplificação eficiente de cada gene, sendo esta eficiência verificada segundo método descrito abaixo. It was made from total RNA extraction Skin samples frozen at -80 9 C Qiazol second method of reagent (Qiagen, USA). For cDNA production, we used the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), with a final cDNA concentration of 3.0 µg. This cDNA was diluted to the concentration required for the efficient amplification of each gene. This efficiency was verified according to the method described below.
As reações de PCR em tempo real foram realizadas utilizando-se o sistema TaqMan™ (Applied Biosystems), que é constituído por um par de primers e uma sonda marcada com um fluoróforo. Para os genes adiponectina e leptina foram utilizados kits TaqMan™ assays (Applied Biosystems) Rn00595250_m1 e Rn00565158_m1 , respectivamente.  Real-time PCR reactions were performed using the TaqMan ™ system (Applied Biosystems), which consists of a pair of primers and a fluorophore labeled probe. For the adiponectin and leptin genes, TaqMan ™ assays (Applied Biosystems) Rn00595250_m1 and Rn00565158_m1 kits, respectively, were used.
O gene GAPD Rat (TaqMan™ - Applied Biosystems), Part number 4352338E, foi escolhido como controle endógeno da reação, o qual serve para normalizar a expressão do gene de interesse nas diferentes amostras. A sonda GAPD está marcada com o fluoróforo VIC, enquanto os primers para os alvos estão marcados com o fluoróforo FAM. The GAPD Rat gene (TaqMan ™ - Applied Biosystems), Part number 4352338E, was chosen as the endogenous control of the reaction, which serves to normalize the expression of the gene of interest in the different samples. The catheter GAPD is labeled with VIC fluorophore, while target primers are labeled with FAM fluorophore.
Antes de se iniciarem os experimentos de quantificação relativa da expressão de qualquer gene, foi realizada a validação do sistema gene alvo, no caso, adiponectina e leptina, com o controle endógeno GAPD rat. Verificamos que as eficiências de amplificação dos genes foram próximas a 100%. Esse passo é essencial para que o controle endógeno possa ser utilizado para normalizar os valores de expressão relativa do gene de interesse.  Before starting the experiments of relative quantification of the expression of any gene, the validation of the target gene system, in this case adiponectin and leptin, was performed with the endogenous control GAPD rat. We found that the amplification efficiencies of the genes were close to 100%. This step is essential for endogenous control to be used to normalize the relative expression values of the gene of interest.
A validação da eficiência dos genes de interesse consistiu na amplificação, tanto com os primers dos genes de interesse quanto com o do controle endógeno, dos cDNAs de triplicatas de concentrações diferentes (diluições seriadas) de uma amostra escolhida aleatoriamente. Em seguida, foi construída uma curva padrão a partir do logaritmo da concentração das amostras pelo Ct [Threshold Cycle: ciclo em que cada curva de amplificação atravessa o limiar de detecção {Threshold), o qual é definido arbitrariamente]. Nessa curva, foram obtidos os valores da inclinação (slope) da curva e da confiabilidade das réplicas (R2). Dessa forma, a eficiência do um sistema foi calculada através da fórmula: E = -| o(" s/ope) -1 . Para a placa de validação dos genes adiponectina, leptina e GAPD, foram feitas triplicatas de uma amostra de cDNA de hepatócito de rato em 7 concentrações diferentes (diluições seriadas de 5x). Validation of the efficiency of the genes of interest consisted in amplifying, with both the gene of interest and endogenous control primers, triplicate cDNAs of different concentrations (serial dilutions) of a randomly selected sample. Then, a standard curve was constructed from the log concentration of the samples by the Ct [Threshold Cycle: cycle in which each amplification curve crosses the detection threshold (Threshold), which is arbitrarily defined]. In this curve, the slope values of the curve and the reliability of the replicas (R2) were obtained. Thus, the efficiency of a system was calculated by the formula: E = - | o ("s / ope) -1. For the adiponectin, leptin and GAPD gene validation plate, triplicates of a rat hepatocyte cDNA sample were made at 7 different concentrations (5x serial dilutions).
Após o cálculo das eficiências de amplificação de cada gene de interesse e do controle endógeno, foi construído um gráfico de dispersão, o qual tem por finalidade definir qual é a amplitude de concentrações para as quais o sistema é eficiente. Para a construção do gráfico, foram utilizados os mesmos valores de logaritmo da concentração das amostras no eixo X e a diferença entre as médias dos Cts do controle endógeno e as médias dos Cts do gene de interesse para cada concentração no eixo Y. A seguir, obteve-se uma linha de tendência para estes valores, a qual possui uma equação de reta na qual é possível verificar o valor da inclinação desta reta. Para que um sistema seja considerado eficiente, o valor da inclinação deve ser menor que 0,1 (quanto mais próximo de zero for este valor, menor é a inclinação da curva e, portanto, mais constante é a diferença entre as médias dos Cts do gene de interesse e do controle endógeno). Os pontos no gráfico, correspondentes às concentrações, que estiverem mais próximos à linha de tendência são considerados validados (o sistema tem 100% de eficiência nestas concentrações). After calculating the amplification efficiencies of each gene of interest and the endogenous control, a scatter plot was constructed, which aims to define the range of concentrations for which the system is efficient. For the construction of the graph, the same logarithm values of the concentration of the samples on the X axis were used and the difference between the means of the endogenous control Cts and the means of the gene of interest for each concentration on the Y axis. A trend line for these values was obtained, which has a line equation in which it is possible to verify the slope value of this line. For a system to be considered efficient, the slope value must be less than 0.1 (the closer this value is to zero, the smaller the slope of the curve is and, therefore, the more constant is the difference between the mean Cts of the gene of interest and the endogenous control). The points on the graph corresponding to the concentrations that are closest to the trend line are considered validated (the system has 100% efficiency at these concentrations).
A concentração de amostra validada como eficiente para os genes adiponectina, leptina e GAPD foi de 40,0 ng de cDNA.  The sample concentration validated as efficient for the adiponectin, leptin and GAPD genes was 40.0 ng cDNA.
Para a quantificação relativa dos genes em estudo, as reações de PCR em tempo real foram realizadas em triplicata a partir de: 6,25μί_ de TaqMan Universal PCR Master Mix (Applied Biosystmes, Foster City, CA, USA) 2x, 0,625μ1_ da solução de primers e sonda, 1 ,625pL de água e 4,0μΙ_ de cDNA (40ng de cDNA) , sendo que no controle negativo, foi adicionado 4,0 μΙ de água ao invés do cDNA. As condições de ciclagem utilizadas foram: 50°C por 2 minutos, 95°C por 10 minutos e 40 ciclos de 95°C por 15 segundos e 60°C por 1 minuto. Os valores da expressão gênica relativa foram obtidos pela análise dos resultados no programa 7500 System SDS Software (Applied Biosystems, Foster City, CA, USA).  For relative quantification of the genes under study, real-time PCR reactions were performed in triplicate from: 6.25μί_ TaqMan Universal PCR Master Mix (Applied Biosystmes, Foster City, CA, USA) 2x, 0.625μ1_ of solution of primers and probe, 1, 625pL of water and 4.0μΙ_ of cDNA (40ng of cDNA), and in the negative control, 4.0 μΙ of water was added instead of cDNA. The cycling conditions used were: 50 ° C for 2 minutes, 95 ° C for 10 minutes and 40 cycles of 95 ° C for 15 seconds and 60 ° C for 1 minute. Relative gene expression values were obtained by analyzing the results in the 7500 System SDS Software program (Applied Biosystems, Foster City, CA, USA).
Os resultados obtidos por dosagem com real-time PCR das citocinas inflamatórias estão descritos abaixo  Results obtained by real-time PCR dosing of inflammatory cytokines are described below.
Os valores obtidos foram os dados calculados de RQ, que é a Quantificação Relativa.  The values obtained were the calculated data of RQ, which is the Relative Quantification.
Os métodos para Quantificação Relativa da Expressão Gênica permitem quantificar diferenças no nível de expressão de um gene específico (alvo) entre as diferentes amostras. A produção de dados é expressa como uma alteração ou diferença no número de vezes nos níveis de expressão. Para o estudo, uma amostra foi escolhida como calibradora e também foi escolhido um gene endógeno para normatizar os resultados. Os resultados normatizados obtidos são sempre relativos ao dado do calibrador. A amostra calibradora utilizada para todos os grupos foi a que apresentou o valor mediano entre as três medições realizadas, para cada dia de tratamento (dois, quatro ou dez dias). Methods for Relative Quantification of Gene Expression allow quantifying differences in the level of expression of a specific gene (target) between different samples. Data production is expressed as a change or difference in the number of times in expression levels. For the study, a sample was chosen as calibrator and an endogenous gene was also chosen to normalize the results. The standardized results obtained are always relative to the calibrator data. The calibrator sample used for all groups presented the median value between the three measurements taken for each day of treatment (two, four or ten days).
Os resultados obtidos mostraram que a adiponectina estava aumentada tecidualmente no D4 e D10 no grupo 3 quando comparada ao grupo controle e aumentada no grupo 4 quando comparada ao lado contralateral. O IGF-1 estava aumentado nos dias 2 e 4 no grupo 3 quando comparado ao grupo controle e tanto no grupo 3 como no grupo 2 quando comparado ao lado contralateral. A IL-6 apresentou melhores resultados teciduais no grupo 3 e no grupo 2 quando comparados ao controle e no grupo 3 e no grupo 4 no D2 quando comparados com o lado contralateral. O IFN-alpha apresentou melhores resultados nos dias iniciais (2 e 4) no grupo 2 e no grupo 4 e, no dia 10, .no grupo 3 quando comparado ao grupo controle. Na comparação com a ferida contralateral, o grupo 2 apresentou melhor resultado. O IFN-gama apresentou melhores resultados nos grupos 2 e 4 em relação ao grupo controle e no grupo 2 em relação às feridas contralaterais. A IL-12, que como os IFN tem ação anti-cicatricial, apresentou menores níveis no grupo 4 quando comparado com o grupo controle e no grupo 2 quando comparada às feridas contralaterais.  The results showed that adiponectin was tissue increased in D4 and D10 in group 3 when compared to the control group and increased in group 4 when compared to the contralateral side. IGF-1 was increased on days 2 and 4 in group 3 when compared to the control group and both in group 3 and group 2 when compared to the contralateral side. IL-6 presented better tissue results in group 3 and group 2 when compared to control and in group 3 and group 4 in D2 when compared to the contralateral side. IFN-alpha showed better results in the early days (2 and 4) in group 2 and group 4 and, on day 10, in group 3 when compared to the control group. In comparison with the contralateral wound, group 2 presented better results. IFN-gamma showed better results in groups 2 and 4 compared to control group and group 2 compared to contralateral wounds. IL-12, which as IFN has anti-healing action, had lower levels in group 4 compared to control group and group 2 compared to contralateral wounds.
O TNF-alpha e a leptina apresentaram melhores resultados no grupo 3 quando comparado ao grupo controle. A leptina esteve aumentada no grupo 2 quando comparada à ferida contralateral.  TNF-alpha and leptin showed better results in group 3 when compared to the control group. Leptin was increased in group 2 compared to the contralateral wound.
A IL-2 apresentou-se aumentada no grupo 3 tanto quando comparado ao grupo controle como às feridas contralaterais. Esta citocina esteve aumentada também no grupo 4 quando comparada ao grupo controle. Não foram observadas variações expressivas quanto à IL-4.  IL-2 was increased in group 3 as compared to the control group and contralateral wounds. This cytokine was also increased in group 4 when compared to the control group. No significant variations were observed regarding IL-4.
Exemplo 4: Elisa (análise de citocinas inflamatórias no soro) Example 4: Elisa (analysis of inflammatory cytokines in serum)
Este ensaio emprega a técnica de imunoensaío sanduíche quantitativo. Um anticorpo monoclonal específico para a substância alvo é pré- adicionado em uma microplaca ainda na fábrica. As amostras, controles e padrões são pipetados para os poços e se a substância em estudo estiver presente será ligada pelo anticorpo imobilizado. Depois de lavar as substâncias não ligadas, um anticorpo policlonal com enzima ligada específica para a substância é adicionado aos poços. Após uma lavagem para remover qualquer reagente anticorpo-enzima não ligado, uma solução de substrato é adicionado aos poços. A enzima de reação produz um produto azul que fica amarelo quando a Solução de Parada é adicionada. A intensidade de medição de cor está em proporção com a quantidade de substância alvo ligado na etapa inicial. Os valores da amostra são então lidos a partir da curva padrão. This assay employs the quantitative sandwich immunoassay technique. A target substance-specific monoclonal antibody is pre-added to a microplate at the factory. Samples, controls and standards are pipetted into the wells and if the test substance is present it will be bound by the immobilized antibody. After washing the substances unbound, a substance-specific enzyme-linked polyclonal antibody is added to the wells. After washing to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells. The reaction enzyme produces a blue product that turns yellow when the Stop Solution is added. The color measurement intensity is in proportion to the amount of target substance bound in the initial step. The sample values are then read from the standard curve.
Para as reações realizadas neste projeto, foram usados kits comerciais de ELISA Quantikine, da R&D Systems (Minneapolis, EUA) para as substâncias IL-6, IGF-1 e TNF-alfa; para as substâncias leptina e adiponectina foram usados kits comerciais fornecidos pela empresa Millipore (St. Charles, Missourí, EUA).  For the reactions performed in this project, commercial R&D Systems (Minneapolis, USA) Quantikine ELISA kits were used for the substances IL-6, IGF-1 and TNF-alpha; For leptin and adiponectin, commercial kits provided by Millipore (St. Charles, Missouri, USA) were used.
As placas dos 5 kits foram analisadas no leitor de microplaca Bio Rad 680, BioRad Laboratories (Hercules, CA, EUA), nos comprimentos de onda de 490 e 570nm, conforme recomendação dos fabricantes.  The plates of the 5 kits were analyzed on the Bio Rad 680 Microplate Reader, BioRad Laboratories (Hercules, CA, USA) at 490 and 570nm wavelengths as recommended by the manufacturers.
As quantificações das citocinas inflamatórias dosadas por técnica Elisa estão sumarizadas na Tabela abaixo:  The quantifications of inflammatory cytokines dosed by Elisa technique are summarized in the Table below:
Tabela 9: Resumo dos valores encontrados nas dosagens das citocinas pelo método Elisa
Figure imgf000034_0001
Table 9: Summary of values found in cytokine dosages by Elisa method
Figure imgf000034_0001
IGF-1 Controle AGE Café cru Torrado  IGF-1 AGE Control Roasted Raw Coffee
Dia 2 594,56 602,21 1029,02 730,48  Day 2 594.56 602.21 1029.02 730.48
Dia 4 767,18 884,84 924,57 813,58  Day 4,767.18 884.84 924.57 813.58
Dia 10 786,54 960,43 616,76 812,59  Day 10 786.54 960.43 616.76 812.59
IL-6 Controle AGE Café cru Torrado  IL-6 AGE Control Roasted Raw Coffee
Dia 2 280,1067 255,5352 243,6248 270,7462  Day 2 280.1067 255.5352 243.6248 270.7462
Dia 4 256,3285 259,4808 251 ,1673 273,7785  Day 4 256.3285 259.4808 251, 1673 273.7785
Dia 10 276,9472 222,9879 225,3636 1 269,0089  Day 10 276.9472 222.9879 225.3636 1 269.0089
Adiponec Controle AGE Café cru Torrado Adiponec AGE Control Roasted Raw Coffee
Dia 2 8,97218 11 ,11608 9,766461 7,92819  Day 2 8.97218 11, 11608 9.766461 7.92819
Dia 4 8,337174 8,712682 9,493863 8,137195 ) Dia 10 l 16,52638 l 13,46616 ) 8,367467 \ 11 ,89413 [ Day 4 8,337174 8,712682 9,493863 8,137195 ) Day 10 1 16.52638 1 13.46616) 8.367467 \ 11.89413 [
Figure imgf000035_0001
Figure imgf000035_0001
Sistemicamente, pode-se observar diferença favorável ao grupo 4 com a IL-6, o IFN-alp a (nos dias iniciais, 2 e 4), o IFN-gama, a leptina, e IL-2, IL-12 (no dia 10).  Systematically, a favorable difference can be observed for group 4 with IL-6, IFN-alp a (in the early days, 2 and 4), IFN-gamma, leptin, and IL-2, IL-12 (in 10th day).
As citocinas que favoreciam a cicatrização no grupo 3 foram o The cytokines that favored healing in group 3 were the
IGF-1 , INF-alpha e a IL -12 (no dia 10). A adiponectina esteve sistemicamente favorável à cicatrização que ocorreu no grupo 2. Neste grupo a IL-12 estava elevada neste grupo, agindo favoravelmente nos dias iniciais (2 e 4). IGF-1, INF-alpha and IL-12 (on day 10). Adiponectin was systemically favorable for healing that occurred in group 2. In this group IL-12 was elevated in this group, acting favorably in the early days (2 and 4).
A IL-4 esteve elevada no grupo , favorecendo a cicatrização.  IL-4 was elevated in the group, favoring healing.
Exemplo 5: Intrepretação estatística das avaliações das citocinas inflamatórias no tecido cicatricial (Real-Tíme PCR) e sistémico (Elisa) Example 5: Statistical interpretation of evaluations of inflammatory (Real-Tíme PCR) and systemic (Elisa) scar tissue cytokines
Na PCR, que avalia a quantidade de citocinas no tecido, foi possível determinar diferença estatisticamente significante favorável ao grupo 3 (do óleo de café cru) quando comparado ao grupo controle para as citocinas: IGF-1 e leptina (apenas no dia 4). Quando comparada a ferida contralateral, as citocinas encontradas em níveis favoráveis à cicatrização para no grupo 3 foram INF-alpha e gama e leptina (no dia 4).  In PCR, which evaluates the amount of cytokines in the tissue, it was possible to determine a statistically significant difference favorable to group 3 (raw coffee oil) when compared to the control group for cytokines: IGF-1 and leptin (only on day 4). When compared to the contralateral wound, the cytokines found at levels favorable for healing in group 3 were INF-alpha and gamma and leptin (on day 4).
Para o grupo 4 (óleo de café torrado) a quantidade de citocinas no tecido com diferença estatística significante foi observada quando foram dosadas apenas a adiponectina e INF-gama quando comparada com o grupo controle e IL-12 quando comparada à ferida contralateral.  For group 4 (roasted coffee oil) the amount of cytokines in the tissue with statistically significant difference was observed when only adiponectin and INF-gamma were compared when compared to the control group and IL-12 when compared to the contralateral wound.
O AGE interferiu favoravelmente na produção tecidual do IGF- , IFN-alpha e IL-12 quando comparados ao grupo controle e do ITN— alpha quando comparado à ferida contralateral.  AGE favorably interfered with tissue production of IGF-, IFN-alpha and IL-12 when compared to the control group and ITN-alpha when compared to the contralateral wound.
Sistemicamente, pela dosagem sanguínea por Elisa, observou-se favorável e diferença estatisticamente significante da IL-2, do IFN-alpha e gama no grupo 4, da adiponectina nos grupos 2 e 4, do TNF-alpha no grupo 2 e da IL-12 nos grupos 2 e 3. Systematically, by the blood dosage by Elisa, it was observed favorable and statistically significant difference of IL-2, IFN-alpha and gamma. in group 4, adiponectin in groups 2 and 4, TNF-alpha in group 2 and IL-12 in groups 2 and 3.
Desta forma, foi possível constatar que o óleo de café torrado foi mais eficaz que o óleo mineral e o óleo de café cru em promover cicatrização nas feridas produzidas nos ratos. Isto foi observado na clínica, na avaliação da área das úlceras e na avaliação histológica.  Thus, it was found that roasted coffee oil was more effective than mineral oil and raw coffee oil in promoting wound healing in rats. This was observed in the clinic, ulcer area evaluation and histological evaluation.
O óleo de café torrado produziu ação cicatricial tecidual com diferença estatística significante quando dosadas a adiponectina e INF-gama e a dosagem sistémica da adiponectina, o IFN-alpha e gama e a IL-2 sugerindo a relevância destas citocinas no processo cicatricial.  Roasted coffee oil produced tissue healing action with significant statistical difference when dosing adiponectin and INF-gamma and the systemic dosage of adiponectin, IFN-alpha and gamma and IL-2 suggesting the relevance of these cytokines in the healing process.
Este efeito sistémico sinaliza para um possível uso medicamentoso do óleo de café, uma vez que muitas dermatoses e outras doenças estão relacionadas à elevada produção de TNF-α, por exemplo, como psoríase e várias doenças reumatológicas. Este efeito sistémico se evidenciou particularmente no segundo dia do experimento.  This systemic effect signals a possible medicinal use of coffee oil, since many dermatoses and other diseases are related to the high production of TNF-α, for example as psoriasis and various rheumatological diseases. This systemic effect was particularly evident on the second day of the experiment.
Localmente estes óleos estimularam ou inibiram a produção de várias das citocinas estudadas. O aumento na produção de IGF-1 , IL-6 e TNF-a no décimo dia foi concordante com os dois óleos de café.  Locally these oils stimulated or inhibited the production of several of the studied cytokines. The increase in IGF-1, IL-6 and TNF-a production on the tenth day was in agreement with both coffee oils.
Frente aos resultados obtidos, fica evidenciado a presença de um agente com ação cicatrizante, não identificado, presente, ou com maior efetividade no óleo de café torrado, em comparação aos demais tratamentos. Sendo assim, o uso de composições a base de óleos de café sistemicamente no tratamento de doenças inflamatórias deverão ser foco de novos estudos, já que existe evidente potencial para a utilização destas substâncias no tratamento de outras dermatoses e outras doenças sistémicas que exigem uso oral ou parenteral das medicações.  In view of the results obtained, the presence of an agent with healing action, unidentified, present, or with greater effectiveness in roasted coffee oil, is evident compared to other treatments. Therefore, the use of coffee oil-based compositions systemically in the treatment of inflammatory diseases should be the focus of further studies, as there is evident potential for the use of these substances in the treatment of other dermatoses and other systemic diseases requiring oral or oral use. parenteral medication.

Claims

REIVINDICAÇÕES
1. Composição caracterizada por compreender os seguintes componentes: 1. Composition comprising the following components:
- Óleo obtido a partir de grãos torrados de café;  - Oil obtained from roasted coffee beans;
- Veículo farmaceuticamente aceitável.  - Pharmaceutically acceptable vehicle.
2. Composição, de acordo com a reivindicação 1 , caracterizada por compreender óleo de café com concentração variando entre 0,001% e 99,999%, preferencialmente 70%.  Composition according to Claim 1, characterized in that it comprises coffee oil with a concentration ranging from 0.001% to 99.999%, preferably 70%.
3. Composição, de acordo com a reivindicação 1 , caracterizada por o óleo de café ser extraído, preferencialmente, do café da espécie Coffea arábica.  Composition according to Claim 1, characterized in that the coffee oil is preferably extracted from coffee of the species Coffea arabica.
4. Composição, de acordo com a reivindicação 1 , caracterizada por o óleo de café compreender qualquer café classificado para bebida.  Composition according to Claim 1, characterized in that the coffee oil comprises any coffee classified for drink.
5. Composição, de acordo com a reivindicação 1 , caracterizada por o óleo de café compreender qualquer tipo de granulometria ou peneira utilizada para a separação por tamanho de grãos.  Composition according to Claim 1, characterized in that the coffee oil comprises any type of grain size or sieve used for size separation.
6. Composição, de acordo com a reivindicação 1 , caracterizada por o óleo obtido a partir de grãos torrados de café compreender um processo de torra capaz de gerar as substâncias que promovem os aromas e o sabor característico da bebida de café realizada por infusão com água quente. Composition according to Claim 1, characterized in that the oil obtained from roasted coffee beans comprises a roasting process capable of generating the flavor-promoting substances and the characteristic flavor of the coffee beverage infused with water. hot.
7. Composição, de acordo com a reivindicação 6, caracterizada por o processo de torra compreender o mesmo utilizado para a produção de grãos destinados ao consumo de bebida. Composition according to Claim 6, characterized in that the roasting process comprises the same process used for the production of beverage grains.
8. Composição, de acordo com a reivindicação 1 , caracterizada por o óleo de café compreender o óleo em sua forma bruta; filtrada, clarificada, semi-refinada; refinada; fracionada; hidrogenada; interesterificado puro; e misturado com outros óleos e/ou ingredientes.  Composition according to Claim 1, characterized in that the coffee oil comprises the crude oil; filtered, clarified, semi-refined; refined; fractionated; hydrogenated; pure interesterified; and mixed with other oils and / or ingredients.
9. Composição, de acordo com a reivindicação 8, caracterizada por o óleo de café compreender, preferencialmente, o óleo em sua forma filtrada ou semi-refinada. Composition according to Claim 8, characterized in that the coffee oil preferably comprises the oil in its filtered or semi-refined form.
10. Composição, de acordo com a reivindicação 1 , caracterizada pelo veículo farmaceuticamente aceitável ser selecionado dentre triglicérides de cadeia média (TCM), solução salina ou tampões, preferencialmente triglicérides de cadeia média (TCM) em um percentual adequado (q.s.p.) para atingir 100% da fórmula com base no peso total da composição.Composition according to Claim 1, characterized in that the pharmaceutically acceptable carrier is selected from medium chain triglycerides (TCM), saline or buffers, preferably medium chain triglycerides (TCM) by an appropriate percentage (qsp) to achieve 100%. % of formula based on total weight of composition.
1 1. Uso da composição, de acordo com as reivindicações de 1 a 10, caracterizada pelo fato de ter aplicação na cicatrização cutânea. Use of the composition according to claims 1 to 10, characterized in that it has application in skin healing.
12. Uso do óleo de café caracterizado por ser aplicado na produção de formulações para cicatrização cutânea.  12. Use of coffee oil characterized by being applied in the production of formulations for skin healing.
13. Formulação caracterizada pelo fato de compreender a composição de acordo com as reivindicações de 1 a 10 em um veículo farmacologicamente aceitável e componentes opcionais selecionados dentre agentes quelantes, agentes ajustadores de pH, agentes conservantes, emolientes, umectantes, agentes bacteriostático, ingredientes ativos, corantes e aromatizantes.  A formulation comprising the composition of claims 1 to 10 in a pharmaceutically acceptable carrier and optional components selected from chelating agents, pH adjusting agents, preservatives, emollients, humectants, bacteriostatic agents, active ingredients, colorings and flavorings.
14. Uso da formulação, de acordo com a reivindicação de 13, caracterizada pelo fato de ter aplicação cicatrização cutânea.  Use of the formulation according to claim 13, characterized in that it has cutaneous application.
15. Uso da composição descrita nas reivindicações de 1 a 10 caracterizado por ser na preparação de um medicamento para cicatrização cutânea.  Use of the composition described in claims 1 to 10 for the preparation of a skin healing medicament.
PCT/BR2013/000459 2012-11-13 2013-11-01 Composition and formulation based on coffee oil, and uses thereof WO2014075157A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRBR1020120291630 2012-11-13
BR102012029163A BR102012029163B8 (en) 2012-11-13 2012-11-13 Use of roasted coffee oil of the coffee arabica species

Publications (1)

Publication Number Publication Date
WO2014075157A1 true WO2014075157A1 (en) 2014-05-22

Family

ID=50730415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2013/000459 WO2014075157A1 (en) 2012-11-13 2013-11-01 Composition and formulation based on coffee oil, and uses thereof

Country Status (2)

Country Link
BR (1) BR102012029163B8 (en)
WO (1) WO2014075157A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023088698A1 (en) * 2021-11-16 2023-05-25 Unilever Ip Holdings B.V. Skin care composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4793990A (en) * 1980-04-02 1988-12-27 L'oreal Use of coffee bean oil as a sun filter
WO1999063963A1 (en) * 1998-06-11 1999-12-16 Sederma Compositions for cosmetic or dermopharmaceutical use containing a mixture of green coffee and shea butter extracts
US6716437B1 (en) * 1993-09-13 2004-04-06 E-L Management Corporation Topical composition and method for enhancing lipid barrier synthesis
BRPI0602842A (en) * 2006-07-20 2008-03-04 Chemyunion Quimica Ltda use of green coffee oil (coffea arabica) in cosmetic and pharmaceutical formulations to maintain skin properties
WO2012013764A2 (en) * 2010-07-30 2012-02-02 Nestec S.A. Use of roasted coffee beans for regulating skin pigmentation
MX2013001076A (en) * 2010-07-30 2013-03-12 Oreal Use of a mixture of roasted and green coffee beans for regulating skin pigmentation.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4793990A (en) * 1980-04-02 1988-12-27 L'oreal Use of coffee bean oil as a sun filter
US6716437B1 (en) * 1993-09-13 2004-04-06 E-L Management Corporation Topical composition and method for enhancing lipid barrier synthesis
WO1999063963A1 (en) * 1998-06-11 1999-12-16 Sederma Compositions for cosmetic or dermopharmaceutical use containing a mixture of green coffee and shea butter extracts
BRPI0602842A (en) * 2006-07-20 2008-03-04 Chemyunion Quimica Ltda use of green coffee oil (coffea arabica) in cosmetic and pharmaceutical formulations to maintain skin properties
WO2012013764A2 (en) * 2010-07-30 2012-02-02 Nestec S.A. Use of roasted coffee beans for regulating skin pigmentation
MX2013001076A (en) * 2010-07-30 2013-03-12 Oreal Use of a mixture of roasted and green coffee beans for regulating skin pigmentation.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REUTER J ET AL.: "Botanicals in dermatology: an evidence- based review.", AM J CLINICAL DERMATOL, vol. 11, no. 4, 2010, pages 247 - 267, XP009156810, DOI: doi:10.2165/11533220-000000000-00000 *
WAGEMAKER T: "Variabilidade do teor de óleo, de seu fator de proteção solar e de outros componentes da fraçâo lipidica do gênero Coffea visando usos alternativos aos grãos.", DISSERTAÇÃO DE MESTRADO. INSTITUTO AGRONÔMICO DE CAMPINAS, 2009, Campinas, SP., pages 15 - 17 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023088698A1 (en) * 2021-11-16 2023-05-25 Unilever Ip Holdings B.V. Skin care composition

Also Published As

Publication number Publication date
BR102012029163B8 (en) 2022-03-29
BR102012029163B1 (en) 2022-02-22
BR102012029163A2 (en) 2014-07-15

Similar Documents

Publication Publication Date Title
Ellis et al. Cyclosporine improves psoriasis in a double-blind study
JP7069490B2 (en) Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system
JP6353073B2 (en) Composition for cell recovery and method for producing and using the same
JP6290531B2 (en) Plectranthus amboinix fraction with anti-arthritic activity
JP5778912B2 (en) IGF-1 secretion promoter
Niezgoda et al. The evaluation of vitiligous lesions repigmentation after the administration of atorvastatin calcium salt and simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial
JP6471302B2 (en) Cell-free composition for cell restoration and method of making and using the same
Wang et al. Ameliorative effects of sea buckthorn oil on DNCB induced atopic dermatitis model mice via regulation the balance of Th1/Th2
Podarala et al. Efficacy of BCG vaccine and Mitomycin C for the treatment of ocular squamous cell carcinoma in bovines
KR102232873B1 (en) Composition for preventing hair loss or promoting hair growth comprising lagerstroemia indica extract
CN109846907A (en) Dermatological compositions containing Escherichia coli and enterococcus faecalis
WO2008047880A1 (en) Therapeutic agent for rheumatoid arthritis
JPH072685A (en) Stabilized standardized pharmaceutical preparation of mistletoe lectin, preparation of concentrate of mistletoe lectin, preparation of pharmaceutical preparation containing mistletoe lectin fraction and medical supply for improving natural immunoresistance and medical treatment of tumor
WO2014075157A1 (en) Composition and formulation based on coffee oil, and uses thereof
JP5403582B2 (en) ATP production promoter
TWI494115B (en) Use of alcohol extract of longan seeds
JP6001789B2 (en) Use of longan seed alcohol extract
JP2021176888A (en) Therapeutic pharmaceutical composition comprising purple corn extract for prevention or treatment of skin disease
KR101418881B1 (en) Lipid water soluble bee venom extracts for improving immunity and for curing inflammation and for curing pain and composition for parenteral medicines and manufacturing method of the same
TWI740342B (en) USE OF PEPTIDE CPPecp DIMER FOR TREATING DERMATITIS
WO2023227087A1 (en) Plectranthus amboinicus extract for use in inhibiting immune responses
KR101836822B1 (en) Composition for preventing or treating psoriasis comprising monoacetyl-diacylglycerol compound
WO2014066968A1 (en) Composition and formulation containing rice oil and uses thereof
KR20190044325A (en) Composition for preventing or treating spinal cord injury comprising Neutrophil elastase inhibitor
EP2859897B1 (en) Pharmaceutical composition for treating wounds or revitalizing skin comprising euphorbia kansui extracts or fractions thereof as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13854628

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13854628

Country of ref document: EP

Kind code of ref document: A1